The response of the lymphatic endothelium to inflammation and infection in in vitro and in vivo systems by Pegu, Amarendra
                                                                i 
 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
 
2007 
of the requirements for the degree of 
Graduate School of Public Health in partial fulfillment  
M. S. Biotechnology, Jawaharlal Nehru University, New Delhi, India, 2002 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
B. Sc. (H) Biochemistry, University of Delhi, Delhi, India, 2000 
Amarendra Pegu 
THE RESPONSE OF THE LYMPHATIC ENDOTHELIUM TO INFLAMMATION AND 
INFECTION 
IN IN VITRO AND IN VIVO SYSTEMS 
 
 
 
 
 
 
 
by 
by 
Amarendra Pegu 
 
It was defended on 
July 17th, 2007 
and approved by 
 
 
Todd A. Reinhart, Sc.D. 
 Dissertation Advisor, Associate Professor,  
Department of Infectious Diseases and Microbiology 
Graduate School of Public Health 
University of Pittsburgh 
 
 
JoAnne L. Flynn, Ph.D. 
Committee member, Professor,  
Department of Molecular Genetics and Biochemistry 
School of Medicine 
University of Pittsburgh 
 
 
Simon Barratt-Boyes, Ph.D., B.V.Sc. 
Committee member, Associate Professor,  
Department of Infectious Diseases and Microbiology 
Graduate School of Public Health 
University of Pittsburgh 
 
 
David N. Finegold, M.D. 
 Committee member, Professor,  
Department of Human Genetics 
Graduate School of Public Health 
University of Pittsburgh 
Graduate School of Public Health 
 
 
This dissertation was presented 
UNIVERSITY OF PITTSBURGH 
                                                                ii 
  
 
 
 
 
 
 
 
 
 
Copyright © Amarendra Pegu 
2007 
 
 
 
 
 
 
 
 
 
                                                                iii 
THE RESPONSE OF THE LYMPHATIC ENDOTHELIUM TO INFLAMMATION 
AND INFECTION 
IN IN VITRO AND IN VIVO SYSTEMS 
 
Amarendra Pegu, PhD 
University of Pittsburgh, 2007 
Todd A. Reinhart, Sc.D. 
 
The lymphatic endothelium is involved in the drainage of interstitial fluid and in the migration of 
immune cells like dendritic cells (DCs) from the periphery to draining lymph nodes (LNs).  
Tuberculosis has been declared a pandemic infectious disease accounting for more than 2 million 
deaths annually and is caused by the intracellular bacteria, Mycobacterium tuberculosis.  The 
chronic inflammatory response to M. tuberculosis infection is characterized by the formation of 
granulomatous structures in the pulmonary compartments of infected individuals.  These 
structures contain excess interstitial fluid and are enriched with immune cells including DCs.  
Therefore, the lymphatic vessels might play important roles in regulating drainage of fluid and 
migration of immune cells from granulomas to the draining LNs.  My hypothesis was that there 
is an increased concentration of lymphatic vessels in these granulomatous structures and that the 
inflammatory environment including mycobacterial components present in granulomas and at 
other sites of infection elicit an inflammatory response from these lymphatic vessels which 
contribute to the overall immune response to M. tuberculosis infection.  To address this 
hypothesis I have examined the distribution of lymphatic vessels in granulomatous and LN 
tissues obtained from nonhuman primates infected with M. tuberculosis and analyzed their 
expression of multiple chemokines and lymphatic markers.  In addition, I evaluated the response 
of LECs to inflammatory mediators that included multiple TLR ligands, M. tuberculosis 
components and cytokines.  I observed an association of lymphatic vessels with granulomas, and 
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found that there was heterogeneity in the expression of chemokines and lymphatic markers by 
LECs in tissues.  I also found that primary human LECs expressed multiple TLR molecules and 
responded to TLR ligands, cytokines and M. tuberculosis components by increasing expression 
of inflammatory chemokines, cytokines and adhesion molecules.  These LECs also demonstrated 
phenotypic similarities with DCs.  Overall my findings support the involvement of the lymphatic 
endothelium in the inflammatory immune response to pathogens like M. tuberculosis.  From the 
perspective of public health relevance, these studies provide direction in the development of new 
therapeutic targets against M. tuberculosis infections and aid in the development of better 
adjuvants for vaccines for infectious diseases and cancers. 
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1.0  INTRODUCTION 
The mammalian vascular system is made up of two distinct but interrelated endothelial networks 
– the blood endothelial network and the lymphatic endothelial network.  The blood endothelial 
network forms a closed loop that is involved in the circulation of blood pumped by the heart, 
whereas the lymphatic endothelial network is a unidirectional, open-ended network comprised of 
lymphatic vessels that collect lymph, a protein-rich exudate from blood vessels, in tissues and 
drain it back into the venous circulation via larger collecting lymphatic vessels and the thoracic 
duct (1,2).  The lymphatic endothelial network is also involved in immune surveillance since 
immune cells that include lymphocytes and antigen-presenting dendritic cells (DCs) travel from 
peripheral tissues through lymphatic vessels to draining lymph nodes (LNs) to initiate specific 
immune responses (3).  Despite the importance of the lymphatic endothelial network in initiation 
of immune responses, there has been a dearth of studies on the involvement of the lymphatic 
endothelial network in the immune system as compared to the extensive research focused on the 
blood endothelial network.  The lymphatic endothelial network can be actively involved in the 
regulation of cellular traffic from the periphery to the LNs, which would be important during 
pathogenic infections for the initiation and maintenance of antigen specific immune responses. 
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1.1 LYMPHATIC ENDOTHELIUM: CELLULAR STRUCTURE AND MARKERS 
The lymphatic endothelial network consists of the terminal lymphatic vessels and the larger 
collecting lymphatic vessels, collectively referred to as the lymphatic endothelium (LE) and 
lymphoid organs that include LNs, tonsils, Peyer’s patches, spleen and thymus, which are 
involved in the generation and maintenance of immune responses (2).  Lymphatic vessels are 
present throughout the body in almost all tissues with the exception of the central nervous 
system, bone marrow and avascular tissues such as cornea, cartilage and epidermis (1,2).  The 
lymphatic vessels share phenotypic similarities with blood vessels although there are key 
differences between them due to their distinct functional roles.  The terminal lymphatic vessels 
are thin-walled, relatively large vessels, composed of a single, non-fenestrated layer of 
overlapping endothelial cells that lack a continuous basement membrane as well as pericyte or 
smooth muscle cell coverage unlike blood vessels.  The lymphatic endothelial cells (LECs) are 
anchored to the extracellular matrix by specialized fibrillin-containing anchoring filaments (4), 
which in the case of fluid accumulation exerts pressure on the LECs to open the overlapping cell 
junctions leading to enhanced  uptake of interstitial fluid, macromolecules, and cells.  The larger 
collecting lymphatic vessels have a smooth muscle layer, basement membrane and luminal 
valves that prevent backflow of fluid.  
Lymphatic vessels were first described in the seventeenth century, although not until at 
the start of the twentieth century was the developmental origin of lymphatic vessels known.  
Only in the past decade were the first growth factors and molecular markers specific for 
lymphatic vessels identified.  Due to the close structural and functional relationship of blood and 
lymphatic vessels, it has been a challenge to differentiate between the two vessel types.  The 
identification of several lymphatic-specific markers has aided in the isolation and study of 
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relatively pure LECs and blood endothelial cells (BECs) from tissues (5-8).  These studies have 
focused on the molecular characteristics of LECs and BECs, and have revealed that both cell 
types share a similar gene expression profile indicative of their close genetic relationship.  
However, these studies have also led to the identification of several new and previously 
unknown markers specific for LECs that will aid in the further study of lymphatic vessel 
development and function. 
1.1.1 VEGFR-3 
Vascular endothelial growth factor receptor-3 (VEGFR-3), also known as Flt4, was one of the 
first lymphatic-specific markers to be identified (9).  VEGFR-3 is a member of the fms-like 
tyrosine kinase family and specifically binds the lymphatic growth factors, vascular endothelial 
growth factor (VEGF)-C and VEGF-D.  During early embryonic development,VEGFR-3 is 
expressed both in developing venous and  in presumptive LE, whereas in normal adult tissues, its 
expression is largely restricted to the LE (9,10).  Although the inactivation of Vegfr3 in mice led 
to cardiovascular failure and death of the embryo before the emergence of lymphatic vessels 
(11), the association of mutations in Vegfr3 gene with hereditary lymphedema in patients has 
provided support for an important role of this gene in lymphatic development (12,13).  VEGFR-3 
expression has also been observed on some blood capillaries associated with tumor 
neovascularization or wound granulation tissue (10,14,15), and on antigen presenting cells in 
corneal tissue (16,17).  Therefore, depending on the tissue and the developmental stage, VEGFR-
3 alone may not be sufficient to serve as a specific marker for lymphatic vessels. 
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1.1.2 Prox1 
The transcription factor Prospero-related homeobox-1 (Prox1) is a homolog of the Drosophila 
homeobox gene prospero (18) and is considered to be the most specific lineage marker in 
endothelial cells for LECs.  Inactivation of Prox1 in mice leads to embryonic lethality and a 
complete absence of lymphatic vasculature in these mice (19).  It was also observed that in Prox1 
null mice, the endothelial cells failed to express LE markers (20) indicating the importance of 
Prox1 in the early stages of LEC differentiation from progenitor cells.  The ectopic expression of 
Prox1 in differentiated BECs was shown to reprogram these cells to adopt a lymphatic phenotype 
(21,22) further illustrating the importance of Prox1 for lymphatic cell differentiation.  Amongst 
endothelial cells, Prox1 expression is observed exclusively in lymphatic vessels of adult tissues 
and tumors (23).  
1.1.3 LYVE-1 
The lymphatic endothelial hyaluronan receptor-1 (LYVE-1) is a transmembrane receptor that 
binds to the glycosaminoglycan hyaluronan and is a homolog of the BEC-specific hyaluronan 
receptor CD44 (24,25).  It was identified as a specific cell surface protein of LECs and 
macrophages (24,26,27), although LYVE-1 expression has also been detected in liver sinusoidal 
endothelial cells (28).  Interestingly, LYVE-1 deficient mice have normal development of the 
lymphatic vasculature and exhibit minimal functional abnormalities (29,30).  LYVE-1 is 
expressed on all embryonic LECs, whereas in adult tissues its expression becomes restricted to 
the terminal lymphatic vessels (31).  
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1.1.4 Podoplanin 
Podoplanin is a mucin-type transmembrane glycoprotein that controls podocyte shape and 
platelet aggregation (32).  Podoplanin expression has been observed in osteoblastic cells, kidney 
podocytes, and lung alveolar type I cells (33), with strong expression in LECs both in vivo and in 
vitro (5,6,22,33,34).  Podoplanin deficient mice die perinatally and have malformed lymphatic 
vessels and diminished tissue drainage (35,36) suggesting the importance of podoplanin in 
lymphatic development.  Podoplanin promotes LEC adhesion, migration and tubulogenesis 
formation in vitro (36). Podoplanin expression also has been observed in several non-endothelial 
cell types particularly in tumors suggesting involvement in tumor progression (37). 
1.1.5 CCL21 
The CC-chemokine ligand-21 (CCL21, also known as 6Ckine, Exodus or SLC) is secreted by 
LECs and not BECs (6) and binds to the CC-chemokine receptor 7 (CCR7).  It has been shown 
to mediate the homing of lymphocytes and migration of antigen-loaded DCs into lymphatic 
vessels and LNs (3,38,39), thus playing an important role in the regulation and activation of 
immune responses.  Besides LECs, CCL21 has also been shown to be highly expressed by cells 
other than LECs in the LN paracortex and therefore limiting its use as a lymphatic marker in 
lymphoid tissues (40). 
Additional markers that have been used to identify lymphatic vessels include the 
chemokine decoy receptor D6 (41,42), 5'-nucleotidase (5'-Nase) activity (43-45), and 
desmoplakin (46).  A large number of previously unknown LEC-specific genes have also been 
identified using microarray analysis which include macrophage mannose receptor 1, reelin, 
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plakoglobin, and integrin α9 (5,22), although their exact functions in LECs is still under 
investigation.   
1.2 CELLULAR TRAFFIC THROUGH LYMPHATIC VESSELS 
Lymphatic vessels not only play an essential role in the drainage of interstitial fluid and 
maintenance of normal fluid balance, but also are important for cellular trafficking and antigen 
delivery that are required for the regulation and initiation of immune responses.  Several 
different immune cell types have been shown to traffic through the lymphatic vessels to the 
draining LNs, which supports the important role of the lymphatic system in immune 
surveillance. 
The cellular traffic moving through peripheral lymphatic vessels was first described as 
containing ‘veiled’ cells of mononuclear lineage and lymphocytes (47-50).  Since then these 
veiled cells were identified as mature DCs, although immature DCs, macrophages and 
monocytes have also been shown to be present within lymphatic vessels (51).   
DCs are professional antigen-presenting cells (APCs) that are regarded as the sentinels of 
the immune system and they act as key regulators of immunity (52).  Immature DCs present in 
the peripheral tissues are capable of phagocytosis and express the chemokine receptor CCR6, 
whereas after activation the mature DCs lose their phagocytic capacity, and express the 
chemokine receptor CCR7 (53-56).  These CCR7-expressing mature DCs are then recruited to 
the lymphatic vessels, which in current models constitutively secrete the CCR7 ligand CCL21, 
leading to the migration of the DCs to the draining LNs (57-59).  The trafficking of DCs through 
the lymphatic vessels occurs at a constitutive level under homeostatic conditions and this traffic 
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Figure 1. Role of lymphatic vessels in the migration of mature DCs from the peripheral tissues to the draining 
LNs.  Immature DCs are recruited to peripheral tissues, where they take up antigen and undergo maturation.  These 
antigen-loaded mature DCs express CCR7 and are recruited by peripheral lymphatic vessels that secrete the CCR7 
ligand CCL21.  These DCs then transit through the lymphatic vessels to reach the subcapsular sinus of draining 
LNs, where they further migrate to the paracortical regions to stimulate naïve lymphocytes. 
 
of DCs can be further increased under inflammatory conditions (57,60-63).  Therefore lymphatic 
vessels serve as a conduit for the migration of DCs from peripheral tissues to the draining LNs. 
In addition to DCs, other cell types have also been described that traffic through the 
lymphatic vessels from the periphery to the draining LNs.  A subset of effector T cells that 
express CCR7 exit peripheral tissues and enter lymphatic vessels to migrate to the draining LNs 
(38,64).  These studies have shown that in two different tissue compartments - skin and lung - 
the exit of T cells from these tissues occur via the afferent lymphatic vessels and is dependent on 
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the expression of CCR7 by the T cells.  It has also been shown that CD4+ memory T cells traffic 
through lymphatic vessels (65).   
A large influx of neutrophils has been observed in lymphatic vessels during inflammatory 
conditions (48,66,67). In addition neutrophils have been shown to rapidly migrate via lymphatic 
vessels after inoculation with M. bovis BCG (68).  These neutrophils were also shown to shuttle 
live bacilli to the draining LNs from the site of inoculation via the lymphatic vessels.  Similarly 
other pathogens have been shown to use the lymphatic vessels to reach the draining LNs from 
peripheral sites of infection and disseminate into other parts of the body (69-72).  
The role of lymphatics in tumor metastasis has begun to gain prominence.  It is now 
widely accepted that cancerous cells can transit through lymphatic vessels and spread to other 
tissue compartments like the LNs (73).  Tumor metastasis to regional LNs represents the first 
step in the dissemination of cancers, particularly skin cancers (2).  Several studies have shown 
that increased levels of the lymphatic growth factors VEGF-C and VEGF-D in tumors promote 
growth of lymphatic vessels and lymphatic tumor spread to the regional LNs (74-76).  The 
inhibition of tumor metastasis by targeting VEGFR-3, the receptor for VEGF-C/D and/or 
blocking its signaling pathway provides further evidence in support of the essential role for these 
lymphatic growth factors in the spread of tumors (77-81).  It has also been noted that lymphatic 
vessels can actively recruit tumor cells and participate in metastasis formation by their secretion 
of CCL21 since some tumor cells are known to express CCR7 (82). 
Lymphatic vessels serve as a conduit for multiple cell types, although the exact 
mechanisms by which they recruit these cell types and the functional significance for the 
subsequent migration of these cell types to the draining LNs have not been identified.  In 
addition these lymphatic vessels can also be subverted by pathogens and cancerous cells for the 
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dissemination of infection or metastasis of tumors.  Therefore, there is a need for better 
understanding of the factors involved in the regulation of cellular traffic through lymphatic 
vessels under both homeostatic and inflammatory conditions. 
1.3 THE LYMPHATIC ENDOTHELIUM IN INFLAMMATION 
The response of the blood endothelium to inflammation has been widely studied and well 
characterized.  In contrast, the effects of inflammation on LECs have not been very well studied.  
For example, there have been conflicting reports on expression of adhesion molecules by LECs 
under inflammatory conditions (83-88).  Although in recent studies that used well characterized 
primary LECs, increased expression of adhesion molecules ICAM-1 and VCAM-1, key 
molecules that control leukocyte trafficking, by LECs after stimulation with inflammatory 
cytokines was observed (89,90).  Therefore, these data taken together with the earlier 
observations of increased cellular traffic through lymphatic vessels under inflammatory 
conditions suggest that LECs respond to inflammatory conditions by increasing expression of 
adhesion molecules that enable a larger number of cells to adhere to LECs and migrate via the 
lymphatic vessels.  The lymphatic vessels might also be stimulated by other inflammatory 
mediators to secrete chemokines and cytokines, which might have effects on the cellular traffic 
in these vessels by the recruitment of specific cell types and affecting the phenotype of 
trafficking cells.  Recent studies have shown that inflammatory cytokines can lead to production 
of chemokines and regulators of leukocyte migration by LECs both in vitro and in vivo which 
might play important roles in regulating the availability of the lymphatic vessels for cellular 
traffic (57,89).  The effects of other inflammatory molecules such as pathogens and their 
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components on LECs remains largely unknown and merits further exploration to understand the 
effects of pathogenic infections on LEC function. 
1.3.1 Toll-like receptors 
Toll-like receptors (TLRs) belong to a family of pattern recognition receptors (PRRs) that 
recognize pathogen-associated molecular patterns (PAMPs) and play important roles in the 
innate and adaptive immune responses to pathogens.  To date, 13 mammalian TLRs have been 
identified, out of which the expression of TLRs 1-10 has been observed in humans (91).  TLRs 
are type I transmembrane proteins with a cytoplasmic Toll/IL-1R domain involved in signal 
transduction and activation of transcription factors leading to induction of proinflammatory 
cytokines, chemokines and costimulatory molecules.  They can be broadly classified into two 
groups based on their subcellular localization with TLR1, TLR2, TLR4, TLR5, TLR6 and 
TLR10 expressed on the cell surface, whereas TLR3, TLR7, TLR8 and TLR9 are localized to 
intracellular vesicles (92).  TLRs recognize conserved signature molecules from a wide range of 
pathogens including bacteria, viruses, fungi and parasites.  TLR2 forms heterodimers with either 
TLR1 or TLR6 and is involved in detection of lipoproteins from gram-positive bacteria and 
mycobacteria (93-95).  TLR2 alone can recognize lipoteichoic acid (LTA) (96), whereas TLR2 
and TLR1 together detect triacylated lipoproteins (94) and TLR2 and TLR6 associate to 
recognize diacylated lipoproteins and peptidoglycan (93,97).  TLR4 recognizes 
lipopolysaccaride (LPS), a characteristic component of the cell wall of gram negative bacteria 
(98,99), and TLR5 is involved in the detection of bacterial flagellin (100).  TLR3, TLR7, TLR8 
and TLR9 are involved in the recognition of viral and bacterial nucleic acids (101).  TLR3 
recognize viral double stranded RNA, whereas TLR7 and TLR8 detect viral single stranded 
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RNA.  TLR9 is involved in the detection of DNA containing unmethylated CpG motifs (CpG), 
which are abundant in bacterial DNA.  The ligand for TLR10 has not been identified yet 
(102,103).  The expression of TLRs by LECs and their responsiveness to PAMPs have not been 
well studied, with only limited analysis of the expression of TLR2 and TLR4 in human intestinal 
lymphatic vessels, although the functional significance of this expression was not examined 
(104).  The expression of TLRs by LECs could play an important role in regulation of the 
cellular traffic through the lymphatic vessels by the production of chemokines and cytokines 
upon engagement of these TLRs.   
Among other inflammatory mediators, arachidonic acid and its metabolites have been 
shown to directly act on lymphatic vessels and are important modulators of lymphatic function 
(105,106).  The use of cyclooxygenase (COX) inhibitors and inhibitors of other pathways of 
arachidonate metabolism led to impairment of lymphatic vessel contractility indicating the 
involvement of arachidonate and its metabolites in lymphatic vessels function (106).  Other 
studies have also demonstrated the regulatory effects of prostaglandins and related metabolites 
on lymphatic function (107,108).  These studies indicate that LECs are regulated by multiple 
immuno-modulators that are generated during inflammation and therefore understanding the 
effects of inflammation on these vessels should include consideration of the net effects of these 
molecules. 
1.3.2 Lymphangiogenesis and inflammation 
Lymphangiogenesis or the growth of new lymphatic vessels has been associated with 
inflammatory processes that can occur during both acute/chronic inflammation and cancer.  
Lymphatic vessels are known to proliferate under inflammatory conditions (109) and pro-
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inflammatory cytokines induce VEGF-C, a lymphatic growth factor, supporting the involvement 
of inflammation in lymphatic vessel growth (110).  Another vascular growth factor VEGF-A has 
been shown to be involved in inflammation-driven lymphangiogenesis both in a model of 
corneal neovascularization (111) and a model of delayed-type hypersensitivity reaction (112).  
Lymphangiogenesis also occurs in LNs in response to inflammation, which was associated with 
an increase in DC migration to the inflamed LNs (113).  In this study B cells were shown to be 
essential for the induction of lymphangiogenesis by their secretion of VEGF-A, thus providing 
further evidence for the role of VEGF-A as a lymphangiogenic factor and the involvement of 
immune cells in inducing lymphangiogenesis during inflammation.  Other lymphangiogenic 
factors that have been identified include neurophilin-2 (114), angiopoietin-1/2 (115-117), 
hepatocyte growth factor (HGF) (118,119), fibroblast growth factor-2 (FGF-2) (120-122), 
platelet-derived growth factor-BB (123,124) and the insulin-like growth factors 1 and 2 (125).  
Therefore, it appears that several lymphangiogenic factors either alone or in complex with each 
other can lead to the growth and proliferation of lymphatic vessels in health and disease (2). 
The role of lymphangiogenesis in the development and maintenance of chronic 
inflammatory diseases has now begun to be more widely studied.  Lymphangiogenesis has been 
observed in psoriasis (112,126,127), human renal transplants undergoing rejection (128,129) and 
in a mouse model of chronic respiratory tract infection with Mycoplasma pulmonis (130). It has 
been proposed that lymphangiogenesis contributes to and maintains the inflammation rather than 
resolves it (83) and that inflammation-driven lymphangiogenesis leads to the development of 
dysfunctional lymphatic vessels (131,132).  These dysfunctional lymphatic vessels might also 
negatively impact DC migration to LNs and inhibit the regulation of the immune response.  
Impaired DC migration has been associated with chronic inflammatory diseases since it has been 
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reported that in Crohn’s disease there was an increased retention of mature DCs in the gut (133).  
Similarly, in psoriasis the ability of DCs to migrate was shown to be impaired (134).  In murine 
models of atherosclerosis, a chronic inflammatory disease of the aorta and arteries, impaired DC 
migration has been demonstrated accompanied by dysfunctional lymphatic vessels (113,135).  
The retention of DCs in inflammatory sites in tissues can lead to increased levels of chemokines 
and cytokines secreted by these DCs that can recruit more leukocytes, thereby contributing to the 
maintenance of the local inflammation and lead to further amplification of lymphangiogenesis 
(83).  The influx of cells and expansion of the lymphatic network at these local sites might 
ultimately lead to the establishment of tertiary lymphoid organs or lymphoid neogenesis, which 
has been reported in several chronic inflammatory diseases (136,137). 
Inflammation can have a multitude of effects on the lymphatic system and depending on 
a variety of factors can either promote the expansion of the lymphatic network or lead to 
disruption in lymphatic function.  The lymphatic vessels not only play an essential role in the 
clearance of excess interstitial fluid from local inflammatory sites, but are also likely to be 
intimately involved in the regulation of the inflammatory process and maintenance of immune 
responses.  They also express chemokine scavenger receptors that can contribute to the clearance 
of inflammatory chemokines from inflammatory sites and help in the resolution of the 
inflammation (41,42,138).  Therefore further study of the lymphatic vessels during inflammation 
and pathogenic infections need to be pursued to obtain a better understanding of the involvement 
of lymphatic vessels in disease processes. 
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1.4 LYMPHATIC DISEASES 
A chronic disfiguring and disabling swelling of one or several limbs due to insufficient 
lymphatic drainage characterizes lymphedema.  Lymphedema can interfere with wound healing 
and enhances susceptibility to infection.  Primary or hereditary lymphedema is a condition with 
no identifiable cause and is generally due to genetic mutations in genes involved in the 
development and regulation of the lymphatic system like missense mutations in the VEGFR-3 
gene, which is the receptor for the lymphatic growth factor VEGF-C (12,139).  In contrast, 
secondary or acquired lymphedema develops when the lymphatic vessels are damaged by 
infection, radiation therapy or when lymph nodes are surgically removed.  The accumulation of 
protein-rich interstitial fluid in tissue is associated with increased recruitment of leukocytes 
including neutrophils, macrophages and DCs (140,141).  It has been observed that patients with 
lymphedema are prone to developing chronic infections and various tumors in the 
lymphedematous limb, suggesting that regional immune surveillance is impaired (142), which 
supports the role of lymphatics as an important contributor to immune responses.  The disruption 
of afferent lymphatic vessels in LNs resulted in the loss of high endothelial venules (HEVs) from 
the LNs and reduced lymphcotye trafficking (143) further indicating the importance of lymphatic 
vessels in multiple aspects of the regulation of cellular traffic to LNs.   
However, the most common form of lymphoedema results from lymphatic filariasis, 
which is caused by the parasitic filarial worms Wuchereria bancrofti and Brugia malayi 
(144,145).  Lymphatic filariasis is a mosquito-transmitted infection that is endemic to the 
tropical areas of the world.  The parasitic worms establish themselves in lymphatic vessels 
during infection, causing disruption to the lymphatic system often leading to development of 
lymphedema and other related pathology.  It has been proposed that filarial lymphedema 
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develops due to the interactions between filarial infection and host genetic risk factors in which 
heightened inflammatory responses and lymphatic drainage following filarial infection combined 
with mutations in genes involved in lymphangiogenesis like VEGFR-3 might lead to the 
development of filarial lymphedema (146).   
Kaposi’s sarcoma (KS) is a vascular tumor that consists of sheets of proliferating spindle 
cells and infection with KS-associated herpesvirus/human herpesvirus-8 (KSHV/HHV-8) is 
essential for KS tumor formation (2,147).  The origin of KS tumor cells is thought to be LECs 
since these spindle cells express multiple lymphatic markers and KSHV infection can reprogram 
differentiated BECs into a LEC phenotype with expression of approximately 70% of the major 
lymphatic lineage specific genes and downregulation of blood vascular genes (148-151).  
Therefore, LECs are not only associated with the metastasis of cancerous cells, but they 
themselves can get infected and lead to the development of vascular tumors like KS. 
1.5 TUBERCULOSIS AND THE LYMPHATIC ENDOTHELIUM 
Tuberculosis (TB) is a chronic infectious disease of the respiratory tract, which kills 
approximately 2 million people each year (152).  Overall one-third of the world’s population is 
currently infected with the TB bacillus, M. tuberculosis, with someone becoming newly infected 
every second.  Only about 5-10% of those infected with the mycobacterium develop disease, 
although due to the breakdown in health services, the spread of HIV/AIDS and the emergence of 
multidrug-resistant TB, there has been resurgence in the number of TB cases resulting in a 
growing global epidemic.  Therefore, renewed efforts to completely understand the various steps 
involved in the disease process are required.   
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1.5.1 Natural history of infection 
Tuberculosis is spread through the air and a person needs to inhale only a small number of M. 
tuberculosis bacilli, expelled by an infectious individual with pulmonary tuberculosis, to get 
infected.  Alveolar macrophages lining the respiratory tract are one of the first cell types to 
encounter and engulf the bacilli by phagocytosis.  Many of these cells are able to kill the 
phagocytosed microorganism, but there remain resting, non-activated macrophages that are not 
able to eradicate the bacilli (153).  These infected macrophages permit the intracellular 
replication of mycobacteria, which then lyse the cells and infect more macrophages.  This cycle 
of infection continues leading to the activation of macrophages, which then secrete inflammatory 
cytokines and chemokines.  The inflammatory chemokines like CCL2, CCL3, CCL4, CCL5, 
CCL7, CXCL8, CXCL9, CXCL10 and CXCL11 lead to the recruitment of inflammatory cells 
like monocytes, neutrophils and activated lymphocytes to the site of infection (154).  The 
accumulation of cells at the site of infection culminates in the formation of structures called 
granulomas.  The granulomatous structures are focal collections of the recruited cells, composed 
of infected and uninfected macrophages, including epitheloid macrophages and giant cells, DCs, 
T cells, B cells, and fibroblasts, and they function as physical barriers to prevent the spread of 
infection.  The cells present within these structures secrete inflammatory mediators, form a focus 
of chronic inflammation and help maintain the granuloma.  For example, TNF-α, a pro-
inflammatory cytokine, affects the expression of chemokines by macrophages, which probably 
influences the local chemokine gradients but certainly affects granuloma formation and 
maintenance (155).  Also, the localized expression of IFN-γ and IFN-γ inducible chemokines in 
granulomatous lung tissues obtained from M. tuberculosis infected cynomolgus macaques, 
suggest a role for these molecules in granuloma formation and maintenance (156).   
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1.5.2 Dendritic cells  
There is an increased accumulation of DCs within the granuloma in tuberculosis (157,158), 
although their exact role in these structures has yet to be conclusively defined.  DCs are 
important for a proper immune response as they can activate naïve T cells in draining LNs for 
which they need to migrate to the lymph nodes from the periphery.  Therefore, there might be a 
need for an increased concentration of lymphatic vessels around tuberculous granulomas to 
facilitate the migration of DCs that are known to accumulate within these structures.  The 
increased concentration of lymphatic vessels around tuberculous granulomas might be induced 
by activated macrophages present in these structures, since they have been shown to secrete 
VEGF-C, which signals through VEGFR-3 on lymphatic cells and promotes lymphangiogenesis, 
on stimulation with inflammatory mediators like TNF-α and LPS (159).  
In inflammatory bowel disease (IBD) it has been observed that there is a proliferation of 
lymphatic vessels under the chronic inflammatory conditions in the gut suggesting the 
involvement of lymphatic vessels in development of IBD (160-162).  It was also shown that in 
Crohn’s disease (CD) there was an association of lymphatic vessels with the granulomas that 
developed during disease (163).  Therefore, in tuberculosis, another chronic inflammatory 
disease characterized by granuloma formation, there might also be an association of lymphatic 
vessels with granulomas.  The inflammatory environment of these granulomas might lead to an 
increased concentration of lymphatic vessels around it, which will facilitate the migration of 
local DCs from the granuloma.  Additionally, in a mathematical model of tuberculosis, it was 
found that delays in DC migration to the draining lymph node could alter the outcome of M. 
tuberculosis infection, defining progression to primary disease or latent infection and reactivated 
tuberculosis (164).  It was seen that when there was no trafficking of DCs, progression to 
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primary disease or reactivation of latent tuberculosis occurred.  Therefore, either the increased 
presence or relative absence of lymphatic vessels around granulomas might alter disease 
outcome since these lymphatic vessels are involved in the trafficking of DCs to the draining 
lymph nodes.   
1.5.3 Co-infection with HIV 
It has also been shown that human immunodeficiency virus type 1 (HIV-1) infection is one of the 
most important risk factors for susceptibility to tuberculosis and reactivation tuberculosis (165).  
Therefore, co-infections of HIV-1 and M. tuberculosis can accelerate or reactivate tuberculosis 
disease, which could be a result of the active immune suppression caused by HIV-1.  In addition 
HIV might cause an impairment of the lymphatic endothelium and its function, which could 
contribute to the acceleration of tuberculosis disease progression in a co-infection model, since 
HIV-1 components can induce apoptosis in endothelial cell cultures (166,166,167,167-169).  It 
has been also seen that during simian immunodeficiency virus (SIV) infection in monkeys, a 
nonhuman primate model for HIV-1 infection and disease, there were changes in DC migration 
and activation which suggested a role in initial viral spread and eventual immunosuppression 
(40,170).  Therefore in the case of tuberculosis, a HIV-1 co-infection could aid in the spread of 
the mycobacteria by DCs early in the infection, which could accelerate disease progression. By 
examining the effects of viral co-infection on the LE and its function in DC migration during the 
development of tuberculosis, we would have a better understanding about cellular trafficking 
through the lymphatic network in HIV-1/M. tuberculosis co-infections.  Thus by obtaining a 
better understanding of the lymphatic network and its role in trafficking of cells in tuberculosis 
disease, we will perhaps be better positioned to elucidate the process of disease development. 
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1.6 SUMMARY 
The LE is important for maintaining fluid balance and regulating cellular traffic from the 
periphery to the LNs.  The study of the role of the LE during pathogenic infections will be 
important in understanding the dynamics of cellular trafficking, lymphatic function and 
inflammatory reactions in development and elimination of infections.  Tuberculosis is a global 
health problem and defining the role of the LE in the development of disease may aid in the 
discovery of novel therapeutic targets for ameliorating infection and the pathology associated 
with it.  Also a better understanding of the role of the LE in regulating cellular traffic to LNs will 
aid in the design of better vaccine strategies for cancer and infectious diseases. 
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2.0  SPECIFIC AIMS 
The lymphatic endothelial network plays an important role during immune responses to 
pathogens and during vaccinations.  The afferent lymphatic vessels act as a conduit for dendritic 
cells (DCs) to migrate from a site of infection to the draining lymph node to activate immune 
cells, whereas the efferent lymphatic vessels are used by activated immune cells to reach the 
systemic circulation from the lymph node.  Therefore, in a Mycobacterium tuberculosis 
infection, the lymphatic endothelial network might play an important role in determining disease 
progression by regulating the trafficking of immune cells to and from the site of infection.  An 
increased concentration of lymphatic vessels at the site of M. tuberculosis infection, 
characterized by granulomatous structures, might help in the trafficking of cells like DCs from 
within these structures to the lymph nodes leading to activation of M. tuberculosis specific 
immune cells.  This increased concentration of lymphatic vessels might be induced by 
macrophages and DCs present within granulomas, since these cell types have been shown to 
secrete inflammatory mediators that can stimulate lymphangiogenesis or the growth of new 
lymphatic vessels.  Also, the LECs might contribute to the immune response by increasing 
secretion of inflammatory molecules in response to the inflammatory environment as well as 
mycobacterial components present at sites of infection.  My hypothesis for this project was 
that during a M. tuberculosis infection, there is an increased concentration of lymphatic 
vessels around granulomas, which is induced by lymphangiogenic factors secreted by 
macrophages and DCs present within these structures, and that the inflammatory 
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environment including mycobacterial components present in granulomas and other sites of 
infection elicit an inflammatory response from these lymphatic vessels which could 
ultimately contribute to the overall immune response to M. tuberculosis infection. 
 
This hypothesis was addressed by the specific aims listed below. 
 
1. To evaluate the response of lymphatic endothelial cells to mycobacterial 
components, cytokines and other inflammatory mediators.  The effects of model M. 
tuberculosis components, cytokines and other inflammatory mediators on cultured model 
LECs were studied by flow cytometry, real-time RT-PCR, and ELISA. 
 
2. To determine the effects of M. tuberculosis, SIV or M. tuberculosis/SIV co-infection 
on the expression of multiple endothelial markers and chemokines by the lymphatic 
endothelial network present in lymph nodes.  Lymph node tissues obtained from 
cynomolgus macaques (Macaca fascicularis), infected with M. tuberculosis, SIV or co-
infected with M. tuberculosis and SIV, were used to assess the distribution of lymphatic 
vessels in LNs by in situ hybridization and immunohistochemical approaches.  
 
3. To study the distribution of the lymphatic endothelial network in pulmonary 
granulomas formed during M. tuberculosis infection or M. tuberculosis/SIV co-
infection.  Granulomatous lung tissues obtained from cynomolgus macaques (Macaca 
fascicularis), infected with M. tuberculosis or co-infected with M. tuberculosis and SIV, 
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were used to assess the distribution of lymphatic vessels and lymphangiogenic factors in 
granulomas by in situ hybridization and immunofluorescence approaches.  
 
These studies provide insight into the basic aspects of the LE and their response to inflammation 
and infection.  I have organized the experimental data into three main chapters, which is 
followed by a final discussion on the important findings of this dissertation.  At first I have 
presented a basic characterization of primary human LECs in terms of their expression of TLR 
molecules and their responsiveness to TLR ligands and inflammatory cytokines.  The next 
chapter contains an evaluation of the expression of lymphatic markers and chemokines by the 
lymphatic endothelial network present in LNs, an important secondary lymphoid organ, both in 
health and infectious disease.  Finally I have presented a study of the lymphatic endothelial and 
DC networks present in pulmonary granulomas formed in cynomolgus macaques infected with 
M. tuberculosis.   
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3.1 PREFACE 
In these studies, primary human LECs were evaluated for their expression of innate immune 
receptors and responsiveness to inflammatory mediators using in vitro model systems.  In this 
chapter I have described experiments and data related to the expression of TLRs by human LECs 
and the responsiveness of human LECs to a panel of ligands for TLR 1-9. These studies have 
shown that human LECs express all TLRs except for TLR7, TLR8 and TLR10 at both mRNA 
and protein levels.  These data have also revealed that LECs are responsive to the ligands for 
most of the TLRs, although there were some key exceptions.  Most notably the model ligands for 
TLR9 did not induce any response from the human LECs despite the expression of both mRNA 
and protein for TLR9 in these cells.  Amongst the TLR ligands that induced responses from the 
LECs, the TLR3 ligand poly(I:C) led to the highest induction in multiple chemokine and 
cytokine genes in the LECs.  I have shown that LECs respond to TLR ligands by increasing 
expression of multiple inflammatory molecules including chemokines, cytokines and adhesion 
molecules.  These data reveal that LECs can be actively involved in the local inflammatory 
reactions by production of inflammatory molecules and they likely can regulate the trafficking of 
different cell types through lymphatic vessels by production of chemokines.   
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3.2 ABSTRACT 
The lymphatic endothelium is the preferred route for the drainage of interstitial fluid from tissues 
and also serves as a conduit for peripheral dendritic cells (DCs) to reach draining lymph nodes.  
Lymphatic endothelial cells (LECs) are known to produce chemokines that recruit antigen-
loaded DCs to lymphatic vessels and therefore are likely to regulate the migration of DCs to 
lymph nodes.  Toll-like receptors (TLRs) are immune receptors that recognize pathogen 
associated molecular patterns (PAMPs) and then signal and stimulate production of 
inflammatory chemokines and cytokines that contribute to innate and adaptive immune 
responses.  TLRs are known to be expressed by a wide variety of cell types including leukocytes, 
epithelial cells and endothelial cells.  Because the TLR expression profile of LECs remains 
largely unexamined, we have undertaken a comprehensive study of the expression of TLR1-10 
mRNAs and protein in primary human dermal and lung LECs as well as in hTERT-HDLECs, 
which display a longer life-span than human dermal LECs.  We found that all three cell types 
expressed TLR1-6 and TLR9.  The responsiveness of these LECs to a panel of ligands for TLR1-
9 was measured by real-time RT-PCR, ELISA and flow cytometry, and revealed that the LECs 
responded to most but not all TLR ligands by increasing expression of inflammatory 
chemokines, cytokines and adhesion molecules.  These findings provide insight into the ability 
of cells of the lymphatic vasculature to respond to pathogens and potential vaccine adjuvants and 
shape peripheral environments in which DCs will acquire antigen and environmental cues.  
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3.3 INTRODUCTION 
The lymphatic endothelium (LE) lines the lymphatic vascular system, which drains interstitial 
fluid from tissues and provides the conduit through which immune cells traffic to draining lymph 
nodes (LNs) constitutively and during infection or vaccination.  Lymphatic endothelial cells 
(LECs) are known to produce chemokines, including CCL21, that can draw cells such as antigen 
loaded dendritic cells (DCs) into the draining lymphatic vessels which they traverse to reach 
secondary lymphoid organs where they stimulate and regulate immune responses (3).  Given the 
critical role DCs play in antigen sampling and regulation of immune function, lymphatic vessels 
clearly have supporting functions in the movement of DCs from the periphery to LNs, but they 
might also have more direct roles in modulating the environments in which DCs capture antigen 
and are shaped to provide environmental instruction (171) to T-lymphocytes in draining LNs.  
One mechanism by which DCs receive information about the peripheral environment and 
acquired antigens is via Toll-like receptor (TLR) signaling.  TLRs belong to a family of pattern 
recognition receptors that recognize pathogen-associated molecular patterns (PAMPs) and 
contribute to the innate and adaptive immune responses to pathogens (92,172).  To date, 13 
mammalian TLRs have been identified, of which the expression of only TLR1-10 has been 
observed in humans (91).  TLRs are type I transmembrane proteins with a cytoplasmic Toll/IL-
1R domain involved in signal transduction and activation of transcription factors leading to 
induction of proinflammatory cytokines, chemokines and costimulatory molecules.  TLRs 
recognize a wide range of PAMPs and many different cell types express subsets of TLRs, which 
may reflect the pathogens that they are likely to encounter. 
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Vaccines deliver target antigens of pathogens or cancer cells to the immune system to 
induce appropriate antigen-specific immune responses, and adjuvants have been used to increase 
the immunogenicity of antigens and the efficacy of vaccines (173,174).  The ligands for TLRs 
present attractive candidates for use as vaccine adjuvants given their generally proinflammatory 
properties, and a number have already been used for this purpose in clinical trials (175,176).   
The contribution of TLR responsiveness in vaccine approaches has focused primarily on 
DCs, which expresses multiple TLRs (177,178), whereas TLR expression and responsiveness 
has not been comprehensively examined in LECs.  The LECs in the draining lymphatic 
vasculature might have more active roles in vaccination outcomes than heretofore anticipated.  
To date, analysis of the expression and function of TLRs in LECs has been limited, and has 
focused on TLR2 and TLR4 in human intestinal lymphatic vessels (104).  The expression and 
engagement of TLRs by LECs could affect the trafficking and modulation of DCs by producing 
chemokines and cytokines.  Increased LEC production of chemokines that can recruit DCs could 
lead to increased DC migration and subsequently stronger immune responses (57).  
Understanding TLR expression and responsiveness profiles in LECs will improve vaccine and 
adjuvant designs that target TLRs.  Toward this end, we have analyzed the expression of TLR1-
10 in primary human LECs from skin and lung and have examined their responsiveness to a full 
panel of TLR ligands by measuring the induction of inflammatory chemokines, cytokines and 
adhesion molecules.  These studies identified subsets of TLRs expressed by LECs in these 
different anatomic compartments and revealed an unanticipated lack of induction of CCL21 
expression.  The patterns of responsiveness of these LECs to TLR ligands provide a foundation 
for formulating vaccines that increase the DC attractive and modulating forces of draining 
lymphatics.  
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3.4 MATERIALS AND METHODS 
LEC cultures 
Primary human dermal (HMVEC-dLy) and lung (HMVEC-LLy) LECs (Cambrex Bio Science) 
were cultured in EGM-2MV medium (Cambrex Bio Science) according to the supplier’s 
suggestions.  hTERT-HDLECs were also cultured in EGM-2MV media as previously described 
(179).   
 
Stimulation of LECs with TLR agonists and cytokines 
Agonists for TLR1-9 (TLR Agonist Kit, InvivoGen) and cytokines (Peprotech Inc.) were used to 
treat confluent monolayers of HMVEC-dLy, HMVEC-LLy and hTERT-HDLECs.  The TLR 
agonists were: TLR1/2, Pam3CSK4 (1 ug/ml); TLR2, heat killed Listeria monocytogenes 
(HKLM, 108 cells/ml); TLR3, poly(I:C) (25 ug/ml); TLR4, Escherichia coli K12 
lipopolysaccharide (LPS, 100 ng/ml); TLR5, S. typhimurium flagellin (1 ug/ml); TLR6/2, FSL1 
(1 ug/ml); TLR7, imiquimod (2.5 ug/ml); TLR8, ssRNA40 (2.5 ug/ml); and TLR9, ODN2216, 
ODN2006, or ODNM362 (10 ug/ml each).  The cytokines used were IL-1β (10 ng/ml), TNF-α 
(1 ng/ml) and Oncostatin M (OSM, 100 ng/ml).  After 24 hr of treatment, culture supernatants 
were cryopreserved and the cells were lysed with Trizol (Invitrogen) to isolate total RNA.   
 
Measurement of TLR expression by real-time RT-PCR and flow cytometry 
Real-time RT-PCR was performed on total RNA samples using commercially available TaqMan 
assays for TLR1-10 (Applied Biosystems) on an ABI Prism 7000 Sequence Detection System 
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(Applied Biosystems) as described (180).  The level of expression for each TLR was measured 
relative to the expression of the endogenous control gene β-glucuronidase.  For flow cytometric 
analysis, cells were stained with either phycoerythrin (PE)-conjugated monoclonal antibodies 
(eBioscience) against TLR1 (GD2.F4, 2.5 μg/ml), TLR2 (TL2.1, 5 μg/ml), TLR3 (TLR3.7, 4 
μg/ml), TLR4 (HTA125, 2.5 μg/ml) and TLR9 (eB72-1665, 4 μg/ml), or fluorescein 
isothiocyanate (FITC)-conjugated monoclonal antibodies (Imgenex) against TLR5 (85B152.5, 
10 μg/ml) and TLR6 (86B1153.2, 10 μg/ml) for surface expression, or for surface and 
intracellular expression after fixation and permeabilization with Cytofix-Cytoperm (BD 
Biosciences).  Stained cells were analyzed using an XL flow cytometer (Beckman Coulter).  
Staining with isotype control antibodies was performed in parallel in all studies.  Flow cytometry 
data were analyzed using the Expo32 software package (Beckman Coulter). 
 
Measurement of TLR responsiveness of LECs 
Real-time RT-PCR (comparative Ct method) was performed as described (180) using 
commercially available TaqMan assays for chemokines, cytokines and adhesion molecules 
(Applied Biosystems).  Culture supernatant levels of CCL20 and CXCL10 (R & D Systems), and 
IL-6 (BD Biosciences), were measured by ELISA.  Flow cytometric analysis was performed to 
detect the expression of VCAM-1 and ICAM-1 on the surface of LECs using FITC- or PE-
conjugated monoclonal antibodies (BD Biosciences) against VCAM-1 (51-10C9, 0.125 μg/ml)  
and ICAM-1 (HA58, 5 μg/ml) respectively, after treatment of the LECs with TLR ligands for 24 
hr.   
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3.5 RESULTS 
TLR expression profiles of primary LECs 
To define the expression of TLRs 1-10 in primary LECs, we first used real-time RT-PCR to 
measure TLR mRNA levels in primary dermal (HMVEC-dLy) and lung (HMVEC-LLy) LECs.  
These were examined in parallel with model LECs, hTERT-HDLECs, which are dermal in origin 
and display a longer life-span due to the ectopic expression of human telomerase reverse 
transcriptase (179).  All three cell populations expressed the lymphatic markers podoplanin and 
VEGFR-3 along with the pan-endothelial marker CD31 on their surface as detected by flow 
cytometry (>95% antigen positive) and they expressed mRNAs for the lymphatic markers 
LYVE-1 and Prox1 as measured by real-time RT-PCR (data not shown) providing confidence in 
the lymphatic lineage of these cells.  
All three LEC populations expressed mRNAs for TLR1-6 and TLR9, whereas the 
mRNAs for TLR7, TLR8 and TLR10 were not detected (threshold cycle values >45).  The 
mRNA encoding TLR4 had the highest level of expression relative to the endogenous control 
gene in all three cell populations (Fig. 2A).  Considering all three cell populations together, 
TLR1-3 and TLR6 mRNAs were expressed to similar levels, whereas TLR5 and TLR9 mRNAs 
were approximately 10-fold lower.  TLR2 and TLR6 mRNAs were expressed the most 
disparately among the three cell populations with TLR2 mRNA 10-fold less abundant in the 
primary lung LECs and hTERT-HDLECs relative to the primary dermal LECs, and TLR6 
mRNA approximately 10-fold lower in the primary dermal LECs.  Overall, however, TLR 
mRNA expression profiles were highly similar amongst the three LEC populations.   
Flow cytometry was used next to measure TLR protein levels on cell surfaces and in 
intracellular compartments of all three cell types (Fig. 2B), focusing on the TLRs that had 
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detectable mRNA expression.  We found that TLR4-6 were expressed on the surface of all three 
cell types although minimally so on the hTERT-HDLECs, and that the surface expression levels 
for TLR5 and TLR6 were similar and higher than those of TLR4.  Interestingly, both TLR3 and 
TLR9 were expressed on the surfaces of all three LEC populations in addition to being expressed 
intracellularly and the levels for TLR9 were higher than TLR3.  We found a surprising lack of 
expression of TLR1 and TLR2 on the surfaces of all three LEC populations, whereas these TLRs 
were expressed intracellularly.  Except for TLR5, we observed higher levels of intracellular 
expression for all TLRs compared to their surface expression on all three LEC types.   
 
Induction of inflammatory chemokines in primary LECs by TLR ligands 
To measure the responsiveness of LECs to TLR stimulation, we treated each cell population with 
a panel of ligands for each of TLR1-9 and measured changes in expression of inflammatory 
molecules.  The findings from this comprehensive set of studies are shown collectively in Fig. 
16.  At sites of inflammation, the engagement of TLRs by their ligands leads to signal 
transduction events which activate transcription of inflammatory genes (91), including 
chemokines.   
We found that out of a total of nine TLR ligands, the LECs responded strongly to five of 
them, which were Pam3CSK4, poly(I:C), LPS, FSL1 and ssRNA40, by increasing expression of 
mRNA (>2 fold change in mRNA) for at least one chemokine (Fig. 3A).  The primary dermal 
LECs responded to the largest number of TLR ligands and also exhibited a higher induction of 
inflammatory chemokine mRNA expression.  Amongst the inflammatory chemokines, the 
mRNAs for the CXCR3 ligands, CXCL9, CXCL10 and CXCL11, were the most highly induced 
by TLR ligands in all three LEC populations, with the model TLR3 ligand, poly(I:C), being the  
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Figure 2. TLR expression by LECs.  (A) Total RNAs from confluent monolayers of HMVEC-dLy, HMVEC-LLy 
and hTERT-HDLEC were analyzed for the expression of mRNAs for TLRs 1-10 by real-time RT-PCR.  (B) 
HMVEC-dLy, HMVEC-LLy and hTERT-HDLECs were also assayed for surface and intracellular expression of 
TLR1-6 and 9 by flow cytometry.  Parallel staining with isotype control antibody is represented by the grey 
histograms, whereas staining with TLR-specific antibodies is represented by the black histograms.  The results in 
(A) and (B) are both from one experiment performed twice with similar results.   
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most potent inducer followed by the TLR8 ligand, ssRNA40, and then the TLR4 ligand, LPS 
(Fig. 3A).  In the primary dermal LECs, the TLR2/6 ligand, FSL1, which is a synthetic 
lipoprotein that represents the N-terminal part of the 44-kDa lipoprotein LP44 of Mycoplasma 
salivarium (181), also increased expression of the mRNAs for CXCR3 ligands, whereas in the 
primary lung LECs and hTERT-HDLECs, FSL1 had only minimal effects on the expression of 
CXCR3 ligand mRNAs.  
The chemokine receptors CCR6 and CCR7 play important roles in the migration of DCs 
via the lymphatics and are expressed on immature and mature DCs, respectively (3).  Therefore, 
we examined whether TLR ligands affect the expression of DC-recruiting CCR6 and CCR7 
ligands by LECs (Fig. 3A).  The mRNA encoding the CCR6 ligand CCL20 was highly induced 
in all three LEC types by most TLR ligands, whereas the mRNA encoding the CCR7 ligand 
CCL21 remained at basal levels or was induced up to 3-fold in the primary LEC populations 
after TLR ligand treatment.  CCL21 was not detected by real-time or standard RT-PCR in 
hTERT-HDLECs, which is consistent with our earlier observations with LECs within LNs (182), 
whereas the other CCR7 ligand, CCL19 was not detected by real-time RT-PCR in any of the 
three cell types (data not shown).  Similar to our findings for the CXCR3 ligands, the TLR 
ligands poly(I:C), LPS and Pam3CSK4 induced high levels of expression of CCL20 mRNA, 
whereas the rest of the TLR ligands had minimal to moderate effects on CCL20 mRNA levels.  
The TLR2/6 ligand, FSL1, also induced expression of CCL20 mRNA in mainly the primary 
dermal LECs.  In contrast to its effects on CXCR3 ligands, the TLR8 ligand ssRNA40 had no 
appreciable effects on CCL20 expression (Fig. 3A).   
We also observed increased expression of mRNAs for the inflammatory chemokines 
CCL5 and CXCL8 generally in all three LEC types treated with the TLR ligands poly(I:C), LPS  
 33 
 Figure 3. Induction of mRNAs for chemokines, cytokines and adhesion molecules in LECs by TLR ligands 
and cytokines.  Confluent monolayers of HMVEC-dLy (De), HMVEC-LLy (Lu) and hTERT-HDLECs (hT) cells 
were treated with TLR ligands (A-B) or cytokines (C) for 24 hr and total RNA from the cells was analyzed for the 
induction of mRNAs for chemokines (A, C), cytokines (B) and adhesion molecules (B, C) by real-time RT-PCR.  
The relative fold-changes for each gene are indicated by their color according to the heat map legend.  The “*” 
indicates that the mRNA for CCL21 was not detected by real-time RT-PCR in total RNA from hTERT-HDLECs 
(threshold cycle values >45).  These data represent data compiled from separate experiments performed with 
duplicate cultures and with duplicate real-time RT-PCR reactions performed on each total RNA preparation.   
 
and Pam3CSK4, with FSL1 also inducing similar changes mainly in the primary dermal LECs 
(Fig. 3A).  The expression of CXCL12 mRNA changed only minimally in the three LEC types 
on treatment with the individual TLR ligands.  
A surprising observation from our studies was the unresponsiveness of all three cell types 
to the TLR9 ligand, ODN2006.  In all three cell types, treatment with ODN2006 led to only 
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minimal changes in the expression of mRNAs encoding any of the chemokines examined (Fig. 
3A).  Since ODN2006 is representative of one of three different types of CpG 
oligodeoxynucleotides (ODNs) that can interact with TLR9, we subsequently examined the 
effects of representative CpG ODNs of the other two types (ODN2216 and ODNM362).  Similar 
to ODN2006, there were minimal changes in expression of the mRNAs for chemokines in all 
three cell types after treatment with either ODN2216 or ODNM362 (data not shown).  These 
results indicate that the TLR9 expressed in primary human LECs is not responsive to model 
TLR9 ligands under the conditions we used.  
To extend the mRNA measurements, we also measured the levels of CCL20 and 
CXCL10 secreted by the LEC populations after treatment with TLR ligands (Fig. 4A and B).  
We found that the levels of CCL20 generally paralleled the induction of its mRNA as observed 
by real-time RT-PCR (Fig. 4A).  The TLR ligands poly(I:C), LPS and Pam3CSK4 led to the 
highest levels of CCL20 secreted by all three cell types with the primary dermal LECs having 
higher values than both the primary lung LECs and hTERT-HDLECs.  Similar to the induction 
of CCL20 mRNA observed in mainly the primary dermal LECs by the TLR2/6 ligand, FSL1, we 
found high levels of CCL20 secreted only by the primary dermal LECs and not the other two cell 
types when treated with FSL1.  The rest of the TLR ligands did not lead to increased secretion of 
CCL20 by any of the three cell types when compared to their respective mock control cultures.   
All three LEC populations secreted nearly undetectable levels of CXCL10 at baseline 
with minimal induction in response to most of the TLR ligands (Fig. 4B).  Only the TLR3 ligand 
poly(I:C) stimulated high levels of CXCL10 secretion by all three cell types, which was 
consistent with the levels of induction of its mRNA.  In addition, TLR ligands Pam3CSK4, LPS 
and FSL1 led to increased secretion of CXCL10 only by the primary dermal LECs, whereas the 
 35 
TLR8 ligand, ssRNA40 led to increased CXCL10 secretion only by the hTERT-HDLECs, 
despite the induction observed in CXCL10 mRNA in both the primary dermal LECs and 
hTERT-HDLECs treated with ssRNA40.  Overall, these data demonstrate that there is a high 
degree of concordance in the induction of both mRNA and protein for chemokines produced by 
LECs, but that there are also important differences in the levels of mRNA and secreted protein. 
 
Induction of cytokines and adhesion molecules in primary LECs by TLR ligands 
TLR stimulation can also induce expression of inflammatory cytokines (92).  Therefore, we 
examined the expression levels of the inflammatory cytokines IL-1β, TNF-α and IL-6, in all 
three LEC populations following treatment with TLR ligands.  Similar to the induction of 
chemokines, we detected increased expression of the mRNAs for all three inflammatory 
cytokines in response to the TLR ligands poly(I:C), LPS and Pam3CSK4.  FSL1 led to induction 
again mainly in the primary dermal LECs (Fig. 3B).  As with chemokines, the levels of induction 
of these cytokines were highest in the primary dermal LECs compared to the other two LEC 
populations.  We also measured the amount of IL-6 secreted by the LECs after treatment with the 
TLR ligands and found that there was concordance in the amount of protein secreted by the 
LECs and the induction in its mRNA levels in all three cell types (Fig. 4C).  We also found that 
in all three cell types, the TLR ligands led to moderate changes in the expression of mRNA 
encoding the lymphatic growth factor VEGF-C and no changes in the expression of mRNA 
encoding VEGF-D. 
Lymphatic endothelium can express leukocyte adhesion molecules such as ICAM-1 and 
VCAM-1 after treatment with inflammatory cytokines (89,90).  These molecules could regulate 
the trafficking of immune cells into and through the lymphatics during inflammation.  In all three  
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Figure 4. Production of CCL20, CXCL10 and IL6 by LECs after treatment with TLR ligands.  Confluent 
monolayers of HMVEC-dLy, HMVEC-LLy and hTERT-HDLECs, were treated with TLR ligands for 24 hr and the 
amount of CCL20 (A), CXCL10 (B) and IL-6 (C) released into the culture supernatants by each cell type were 
measured by ELISA.  These results represent the average (+/- SEM) of duplicate cultures with each supernatant 
measured in duplicate by ELISA.   
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LEC populations, ICAM-1 and VCAM-1 mRNA levels were increased in response to the TLR 
ligands poly(I:C), LPS and Pam3CSK4, with FSL1 again inducing expression mainly in primary 
dermal LECs (Fig. 3B).  Although the primary lung LECs were generally less prone to express 
inflammatory molecules upon TLR stimulation, they universally upregulated VCAM-1 
expression after treatment with any of the TLR ligands.  In concordance with the induction in 
their mRNA levels, there was an increase in the expression of ICAM-1 and VCAM-1 on the 
surfaces of all three cell types in response to poly(I:C) and LPS, whereas ODN2006 did not lead 
to changes in their surface expression (Fig. 5).  Finally, in all three cell types, TLR ligands led to 
minimal changes in the expression of the mRNA for LE-specific scavenger receptor, chemokine 
receptor D6, except for moderate induction in the primary lung LECs (Fig. 3B).  These data 
indicate that LECs respond to TLR ligands by increasing production of inflammatory cytokines 
and expression of adhesion molecules on their surface, whereas the expression of lymphatic 
growth factors and scavenger receptors by LECs are minimally affected. 
 
Induction of inflammatory molecules in primary LECs by cytokines 
Cytokines produced as a result of inflammation can have effects on the phenotype and function 
of local lymphatic vessels (89,90).  In addition, injection of TNF-α into skin can lead to 
increased expression of CCL21 by lymphatic vessels (57), although the mechanism of this 
induction is a matter of debate since in a later report, a pleiotropic cytokine, oncostatin M 
(OSM), and not TNF-α, directly enhanced expression of CCL21 by endothelial cells (183).  
Therefore, to understand better the effects of cytokines on LECs, we treated the three LEC 
populations with the cytokines IL-1β, OSM and TNF-α and measured changes in the expression 
of a subset of chemokines, cytokines and adhesion molecules.  With all three cell populations,
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Figure 5. Surface expression of adhesion molecules by LECs after treatment with TLR ligands. Confluent 
monolayers of HMVEC-dLy, HMVEC-LLy and hTERT-HDLECs were treated with the indicated TLR ligands for 
24 hr and the level of surface expression of ICAM-1 and VCAM-1 in these cells was then assayed by flow 
cytometry.  The quad gates were set based on analysis of parallel staining with isotype control antibodies.   
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IL-1β led to the highest level of induction of CCL20 and CXCL10 mRNAs, whereas TNF-α and 
OSM had more moderate effects on the levels of these immunomodulators (Fig. 3C and Fig. 4).  
Interestingly, only OSM induced the expression of CCL21 and only in the primary LEC 
populations.  We also found that there were minimal changes in the expression of CXCL12 by 
all three cell types in response to IL-1β and TNF-α, whereas OSM led to a slight increase in the 
mRNA levels for CXCL12.  The adhesion molecules ICAM-1 and VCAM-1 were both highly 
induced in all three cell types in response to IL-1β and TNF-α but not OSM, which is similar to 
earlier reports of increased expression of these adhesion molecules in TNF-α treated LECs 
(89,90).  
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3.6  DISCUSSION 
Here we present a comprehensive analysis of the expression of TLRs by primary LECs, as well 
as the cell line hTERT-HDLEC, and the effects of TLR stimulation on the induction of key 
molecules involved in regulating cellular traffic through lymphatics.  Our findings provide 
insight into PAMP-specific induction of immunomodulatory molecules by LECs and their ability 
to contribute to shaping the immune response by helping to move DCs to draining LNs and by 
exposing DCs to cytokines, chemokines, and adhesion molecules during transit through the 
lymphatics. 
Our studies revealed that LECs expressed a large repertoire of TLR molecules comprised 
of TLR1-6 and TLR9, and identified a number of interesting aspects of TLR biology in these 
cells.  The expression of a large set of TLRs suggests that LECs have the ability to respond to 
many microbes that could be encountered in peripheral tissues.  Interestingly, despite expression 
of low levels of TLR5 and high levels of TLR9 by all three LEC populations examined, 
treatment with their respective ligands did not induce proinflammatory mediators.  These 
findings are consistent with studies performed with human vascular endothelial cells from the 
same supplier as our LECs (184) and suggest that there are defects in ligand uptake or post-
binding signaling in these cells that might otherwise be intact in the context of whole tissues.   
The responsiveness of the three LEC populations to specific PAMPs suggests that these 
cells will respond to the corresponding pathogens including: gram-positive bacteria through 
TLR1/2 (94,95); gram-negative bacteria through TLR4 (98,99); mycobacteria through 
TLR2/TLR6 heterodimers (97); and viral replication intermediates through TLR3 (101).  The 
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lack of responsiveness of dermal and lung LECs to TLR5 ligand might be related to the 
expression of flagellin by primarily motile, enteric bacteria (100), which will not be encountered 
in the skin and lung at the same frequency as in the gut.  More generally, the higher overall 
responses of the primary dermal LECs to PAMPs and cytokines might be related to the anatomic 
origin of the cells, since excessive inflammatory responses in the lungs would likely be more 
detrimental than similar responses in the skin. 
The responsiveness of the LECs to TLR ligands did not completely correlate with the 
levels of expression of the corresponding TLRs, as determined by flow cytometry.  For example, 
total cellular TLR4 levels were not abundant, yet LPS potently induced chemokines, cytokines, 
and adhesion molecules.  In contrast, TLR9 was abundantly expressed on cell surfaces and 
intracellularly, yet multiple CpG ODNs only minimally induced a limited number of targets.  
LECs, therefore, appear to express a non-functional TLR9 protein, similar to TLR9 expression in 
some instance by keratinocytes, myeloid DCs (185), and HMVECs (184).  Despite our inability 
to detect TLR8 mRNA, the model TLR8 ligand, ssRNA40, nevertheless induced CXCR3 ligand 
expression, suggesting that ssRNA40 might be recognized by another PRR such as RIG-I 
(172,186). 
Afferent lymphatics are a conduit for the migration of antigen-loaded DCs from the 
periphery to draining LNs where they stimulate and shape immune responses.  The expression of 
CCL21 by LECs is involved in this DC migration, since mature DCs (mDCs) express high levels 
of CCR7 (3).  Treatment of skin with inflammatory cytokines can lead to increased production of 
CCL21, which in turn enhances migration of mDCs to draining LNs (57), although the exact 
mechanism of this induction is not clear (183).  We did not observe increased expression of 
CCL21 mRNA above baseline levels in primary LECs in response to any TLR ligand, and 
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CCL21 was not expressed to detectable levels by the hTERT-HDLECs.  In addition, the only 
cytokine in our studies that led to induction of CCL21 by LECs was OSM, which is consistent 
with previous findings in mixed endothelial cell populations (183).  The lack of CCL21 
expression by hTERT-HDLECs and the lack of its induction in the primary dermal and lung 
LECs suggest there might possibly be environmental cues from neighboring cells in these tissues 
that provide signals for basal and increased CCL21 expression.  Additionally, in LNs CCL21 is 
expressed mainly by cells other than LECs (182).   
In contrast, the CCR6 ligand CCL20 was induced upon stimulation of most TLRs, 
particularly by the dermal LECs.  CCL20 could recruit CCR6+ immature DCs (iDCs) to tissues 
harboring stimulated afferent lymphatic vessels.  The recruited iDCs could acquire antigen, 
mature through perhaps the same signals that were received by the LECs or alternatively 
produced by the LECs, and carry antigen to draining LNs.  TLR-mediated induction of ICAM-1 
and VCAM-1, which bind to the integrins LFA-1/Mac-1 and VLA-4, respectively, will also 
contribute to the movement of antigen-loaded DCs across the endothelial lining (39).  The 
CCL20/CCR6 axis might also have a role in this movement of DCs into lymphatic vessels during 
inflammation, as well as movement to the interface between the afferent lymphatics and LN 
parenchyma (182).  Previous findings suggest that CCL20 is involved in recruitment of CCR6+ 
DCs into LNs (187).  Apart from iDCs, CCR6 is also present on effector and memory T cells 
(188), a major proportion of regulatory T cells (189,190), and naïve and memory B cells (191).  
Thus CCL20 expressed by afferent LECs could contribute to the trafficking of multiple cell types 
and thereby help determine the net effects on cell influx and egress in peripheral tissues and 
associated draining LNs.  Finally, increased production of CCL20 and other chemokines will 
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also comprise an innate immune response at the site of TLR stimulation due to the direct 
antimicrobial properties of these proteins (192,193). 
TLR ligands induced expression by LECs of additional inflammatory chemokines 
including CXC9-11, CXCL8, and CCL5.  Cells expressing receptors for these chemokines could 
be recruited into environments containing stimulated lymphatic vessels, and this may represent a 
pathway for the recirculation and clearance of immune effector cells during inflammation.  Basal 
production of inflammatory chemokines by LECs has been reported (194) and our findings here 
demonstrate that PAMPs induce high levels of these inflammatory mediators.  Such pathogen-
driven inflammatory responses could contribute to dissemination of organisms, such as by 
CXCL8-mediated recruitment of neutrophils harboring live bacteria (68).  TLR stimulation of 
LECs also induced expression of the inflammatory cytokines IL-1β, TNF-α and IL-6, with IL-1β 
induced to the highest levels amongst these cytokines.  Therefore, LECs are likely to be an 
important source of inflammatory cytokines during pathogen-driven inflammation.  LECs in turn 
respond to inflammatory cytokines by upregulating chemokines, adhesion molecules, and other 
cytokines, indicating that LECs are also affected by the local inflammatory milieu present at sites 
of infection or vaccination.  LECs could contribute to amplification of inflammatory processes at 
sites of infection or vaccination, both by producing and responding to inflammatory modulators.  
Overall these data indicate that LECs recognize PAMPs, actively contribute to the inflammatory 
process, and are not simply a passive conduit for cellular and fluid traffic. 
Our findings suggest that LECs might have active roles in chronic inflammatory diseases.  
For example, in inflammatory bowel disease (IBD) there is increased proliferation of intestinal 
lymphatic vessels, which was suggested to be the result of chronic inflammation (161,162).  
Increased numbers of intestinal lymphatic vessels could represent a potent source of 
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inflammatory mediators that contribute to chronic inflammation in the gut.  Similarly, in a 
transgenic model of psoriasis it has been suggested that lymphatic hyperplasia contributes to 
inflammation (112).   
Defined TLR ligands are attractive vaccine adjuvants.  Our findings indicate that LECs 
will actively respond to such adjuvants and contribute to shaping the environment in which local 
DCs acquire antigens and begin to undergo a maturation program.  We have shown here that not 
all TLR ligands are equivalent in modulating expression of molecules that impact on the 
recruitment and trafficking of DCs and other immune cells by LECs, indicating that further study 
of the impact of individual or combined TLR ligands on vaccine potency should prove valuable.  
Finally, our findings underscore the need to recognize the lymphatic endothelium as an important 
active participant in host responses to infection and vaccination.    
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4.1 PREFACE 
After the phenotypic characterization of LECs, I next analyzed the distribution of the lymphatic 
endothelial network in immune inductive sites during health and infection.  In this section I have 
described published data related to expression of LEC markers and chemokines by the lymphatic 
endothelial network of lymph nodes.  This chapter contains data from ISHs for LEC marker and 
chemokine mRNAs that were detected in LNs from a cohort of healthy animals and animals 
infected with either M. tuberculosis, SIV or both.  At the start of this project I obtained partial 
cDNA clones for endothelial specific markers to generate riboprobes for use in the ISH studies 
(Appendix A).  These studies have revealed that there is heterogeneity in the expression of 
lymphatic markers and chemokines by the lymphatic endothelial network present in LNs.  In 
LNs from healthy animals, I observed the expression of the LEC marker LYVE-1 mRNA almost 
exclusively by the LECs present at the efferent interfaces of LNs, whereas mRNAs for the other 
LEC markers podoplanin, prox1 and VEGFR3 were expressed by LECs present at both the 
afferent and efferent interfaces of LNs.  I also found that CCL20 mRNA was expressed only by 
LECs at the afferent interfaces of LNs and at very low levels in LNs from healthy animals.  In 
LNs from infected animals, there was an increased expression of CCL20 mRNA by the LECs at 
the afferent interfaces of LNs indicating that either the infection or the inflammatory 
environment due to the infection lead to the increased expression of CCL20 by these LECs.  This 
was further supported by the in vitro data in which I found that both poly(I:C) and γ-irradiated 
M. tuberculosis lead to increased production of CCL20 by model LECs.  Overall these studies 
provide a comprehensive definition of the lymphatic endothelial network of LNs. 
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4.2  ABSTRACT 
Background:  Lymph nodes (LNs) are important sites of connection between the sampled 
peripheral tissues, the many cells of the immune system, and the blood.  The organization of the 
interface between the afferent and efferent lymphatic vasculature and LN parenchyma is 
incompletely understood, and obtaining a better understanding of these tissue microenvironments 
will contribute to an improved understanding of overall lymphatic function.  Methods and 
Results:  We used histologic approaches to define the distributions of cells expressing lymphatic 
endothelial cell (LEC) markers in LNs from healthy, simian immunodeficiency virus (SIV) 
infected, or Mycobacterium tuberculosis infected cynomolgus macaques.  Cells at the afferent 
and efferent interfaces of LNs from all animals showed differential expression of LEC markers, 
with podoplanin, Prox-1 and VEGFR3 expressed in both microenvironments, but with LYVE-1 
expressed only at the efferent interface.  The chemokine CCL20 was uniquely expressed at the 
afferent interface by cells co-expressing podoplanin, and this expression was increased during 
SIV or M. tuberculosis infection.  In contrast, only a small proportion of cells expressing the 
CCR7 ligand CCL21 co-expressed podoplanin.  Treatment of model LECs with the TLR3 ligand 
poly(I:C) or γ-irradiated M. tuberculosis increased production of CCL20 without altering CCL21 
or LEC marker expression.  Conclusions:  This study provides a comprehensive mapping of the 
organization of the lymphatic endothelial network entering and exiting LNs in health and in 
chronic infectious diseases in a nonhuman primate model.  The differences we have defined 
between the afferent and efferent interfaces of LNs could inform the future design of vaccines 
and immunotherapies. 
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4.3 CONDENSED ABSTRACT 
Lymph nodes (LNs) are important sites of connection between peripheral tissues, immune cells, 
and blood.  Histologic approaches were used to define the distributions of cells expressing 
lymphatic endothelial markers in LNs from healthy, simian immunodeficiency virus (SIV) 
infected, or Mycobacterium tuberculosis infected cynomolgus macaques.  Cells at the afferent 
and efferent interfaces of LNs showed differential expression of a subset of lymphatic markers 
and the chemokine CCL20.  CCL20 and LYVE-1 expression at the afferent interface was 
increased during infection.  This study provides a comprehensive mapping of the afferent and 
efferent interfaces in LNs in health and in models of chronic infectious diseases. 
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4.4 INTRODUCTION 
The lymph node (LN) is an important secondary lymphoid organ involved in the initiation and 
maintenance of humoral and cellular immune responses (195-197).  LNs are components of the 
lymphatic system that drain interstitial fluid and immune cells from peripheral tissues and back 
into the blood.  The lymph enters a LN via the afferent lymphatic vessels which either terminate 
at the subcapsular sinus or penetrate into the cortex, and leaves by the efferent lymphatic vessels 
that collect in the medullary sinus (3,197).  These lymphatic vessels have been collectively 
referred to as the lymphatic endothelium although there likely are phenotypic differences 
between afferent and efferent lymphatic vessels due to their different roles in moving things to or 
from LNs. 
Lymphatic vessels contribute to the migration of cells out of peripheral tissues and into 
LNs due in part to the production of chemokines.  Lymphatic endothelial cells (LECs) can 
produce and secrete the homeostatic chemokine CCL21, a CCR7 ligand most recognized for its 
control of the recruitment of  mature DCs and naïve T cells into the paracortices of LNs 
(198,199).  LECs can also secrete inflammatory chemokines including CXCL9, CCL6 and 
XCL1,(194) and their treatment with inflammatory cytokines leads to increased expression of 
chemokines CCL21, CCL20 and CCL2 (6,57,200).   
Lymphatic vessels have been identified using a number of recently discovered markers, 
which include the vascular endothelial growth factor receptor 3 (VEGFR3) (9,201,202), the 
lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) (24,26), podoplanin (34,203), and 
Prox-1 (19,20,204).  Although these markers have been used to identify lymphatic vessels in 
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studies focused on the role of lymphatic vessels in LN tumor metastasis, there has not been a 
comprehensive analysis of their relative expression patterns at the afferent and efferent interfaces 
of LNs, nor of the effects of infectious agents on these patterns of expression in vivo.  In the 
current study we have addressed these issues and have determined that both LEC marker and 
chemokine expression distinguish the afferent and efferent interfaces of LNs and that these 
patterns are modulated by the persistent pathogens simian immunodeficiency virus (SIV) and 
Mycobacterium tuberculosis.   
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4.5 MATERIALS AND METHODS 
Animals and tissue processing 
All animal studies were performed under the guidance and approval of the University of 
Pittsburgh Institutional Animal Care and Use Committee (IACUC).  Adult cynomolgus 
macaques (Macaca fascicularis) were inoculated with virulent M. tuberculosis (Erdman strain) 
via bronchoscope into the lower right lobe or intravenously (I.V.) with SIV/DeltaB670 primary 
isolate as described (40,156,205-207).  At necropsy, the LN tissue specimens were fixed by 
immersion in fresh 4% paraformaldehyde (Sigma Co., St. Louis, MO)/phosphate buffered saline 
(Biowhittaker, Walkersville, MD) (PF/PBS) and processed as described (207,208).   
 
Cloning of endothelial cell markers 
Partial cDNA fragments were generated from rhesus macaque total cellular RNA by RT-PCR as 
described (209).  Total cellular RNA was obtained from snap-frozen tissues using Trizol (Life 
Technologies, Rockville, MA) and reverse transcription was performed using oligo-dT primers 
(Reverse Transcription System, Promega Corp., Madison, WI).  The cDNAs generated were 
amplified by PCR using gene-specific primers designed from human sequences available in the 
GenBank database.  The amplified products were ligated into pGEMT vector (Promega Corp.) 
and DNA sequenced.  The Vector NTI Advance software package (Invitrogen) was used for 
analysis of the resulting DNA sequences.  The probes used here ranged in size from 530nt to 
629nt (45-62% GC content) for LEC markers, and 291nt to 396nt (45-58% GC content) for 
chemokines.     
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 In situ hybridization and immunohistochemical staining 
In situ hybridization (ISH) with [35S]-UTP-labeled riboprobes, immunohistochemical staining 
(IHC), and combined ISH/IHC were performed as described (40,207,208).  Autoradiographic 
exposure times were 21 days for the Prox-1, LYVE-1, VEGFR3 ISHs; 7 days for CCL20 and 
CCL21 ISHs; and 14 days for M. tuberculosis 16s rRNA ISHs.  An anti-human podoplanin 
antibody was used for IHC detection of podoplanin (AngioBio, Del Mar, CA).  
  
Cells and culture 
hTERT-HDLECs (kindly provided by Dr. M.S. Pepper of The University of Geneva) were 
cultured in EGM-2MV media (Cambrex Bio Science Inc, Walkersville, MD, USA) as previously 
described (179).  Poly(I:C) (InvivoGen; 25 µg/ml) and γ-irradiated M. tuberculosis H37Rv 
(Colorado State University, Fort Collins, CO; 500 µg/ml) were used to treat confluent 
monolayers of hTERT-HDLECs.  At specified time intervals, the cells were lysed with Trizol 
(Invitrogen) to isolate total RNA and the culture supernatants were cryopreserved.  Total RNAs 
were then treated with DNase (Ambion) and further purified with RNeasy columns (Qiagen) as 
described (180).  Real-time RT-PCR (comparative Ct method) was performed as previously 
described using predeveloped assays for CCL20 and CCL21 (Applied Biosystems) on an ABI 
Prism 7000 Sequence Detection System (Applied Biosystems) (180).  CCL20 protein levels in 
the culture supernatants were measured by ELISA (R & D systems). 
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4.6 RESULTS 
Differential distribution of lymphatic endothelial markers in LNs 
To determine the relative distributions of multiple LEC markers in LNs in health and during 
persistent infections, we examined LNs obtained from cynomolgus macaques that were 
otherwise healthy or infected with either SIV, M. tuberculosis or both (Table 1).  We determined 
the patterns and levels of LEC marker expression directly in sections of LNs that drained two 
different mucosal sites, including hilar LN (HLN), which drains the lungs, and mesenteric LN 
(MLN), which drains the gastrointestinal tract. 
Table 1. STUDY ANIMALS 
 
Animal Pathogen Duration of infection (wk) Clinical Statusa 
 
M6802 None - Healthy 
M6202 None - Healthy 
M5602 None - Healthy 
M7102 None - Healthy 
M7100 M. tuberculosis 9 Moderate disease 
M7200 M. tuberculosis 41 Advanced disease 
M11301 M. tuberculosis 33 Advanced disease 
M15100 M. tuberculosis 17 Moderate disease 
M15300 M. tuberculosis 11 Advanced disease 
M3001 SIV and M. tuberculosis 9 Advanced disease 
M3002 SIV and M. tuberculosis 8 Advanced disease 
M3101 SIV and M. tuberculosis 11 Advanced disease 
M3202 SIV and M. tuberculosis 7 Advanced disease 
M2601 SIV and M. tuberculosis 8 Advanced disease 
M6002 SIV 2 Acute infection 
M7402 SIV 2 Acute infection 
M7802 SIV 2 Acute infection 
M5702 SIV 2 Acute infection 
 
aCynomolgus macaques infected with M. tuberculosis for the indicated time period were considered to have 
moderate or advanced disease based on antemortem chest radiographs and postmortem gross and microscopic 
pathological evaluation.  Cynomolgus macaques infected with pathogenic SIV were classified as in the midst of 
acute infection, as virus replication typically undergoes and initial systemic burst between days 7-21 PI.   
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Cells expressing LEC markers were identified by ISH using radioactively-labeled, gene-
specific riboprobes for mRNAs encoding LYVE-1, Prox-1 or VEGFR3.  In both the HLN and 
MLN tissue compartments of uninfected animals, we observed expression of mRNA for all three 
markers, although their distributions and levels of expression differed from each other (Fig. 6).  
LYVE-1 mRNA was expressed to the highest level on a per cell basis among the three markers, 
whereas Prox-1 mRNA expression was more moderate, and VEGFR3 mRNA expression was 
lowest in these LN cells.  Cells expressing Prox-1 and VEGFR3 mRNAs were found in the 
subcapsular, cortical and medullary regions of LN (Fig. 6A, B, E, and F), whereas those 
expressing LYVE-1 mRNAs were localized nearly exclusively in medullary and discrete cortical 
regions (Fig. 6C and D).  These data indicate that in LNs from healthy animals, Prox-1 and 
VEGFR3 were expressed by cells at both the afferent and efferent interfaces in LNs, whereas 
LYVE-1 was selectively expressed by cells at the efferent interface.   
Cells expressing Prox-1 and VEGFR3 mRNAs were similarly distributed within HLN 
and MLN tissue compartments even after infection with either SIV, M. tuberculosis, or both 
pathogens.  With the exception of a subset of cells expressing LYVE-1 mRNA in subcapsular 
regions in LNs from infected animals, nearly all of the cells expressing LYVE-1 mRNA were 
localized to medullary regions, as was observed in uninfected animals.  
  Podoplanin is an additional marker used to identify LECs (34,37,210,211).  To provide 
further confidence of the lymphatic lineage of cells expressing Prox-1, VEGFR3, or LYVE-1 
mRNAs, we performed simultaneous ISH and IHC using riboprobes specific for these mRNAs 
and a podoplanin-specific antibody on the same LN tissue sections.  Subsets of cells in 
subcapsular, cortical and medullary regions of LNs expressed podoplanin (Fig. 7).  Among the 
podoplanin+ cells, nearly all of them expressed Prox-1 mRNA, whereas only a subset expressed 
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Figure 6. In situ hybridization detection of LEC marker mRNAs in normal macaque LNs.  LN tissue sections 
from an uninfected cynomolgus macaque were hybridized in situ with [35S]-labeled riboprobes specific for Prox-1, 
LYVE-1 or VEGFR3 mRNAs, as indicated.  (A-B), (C-D) and (E-F) are different regions on the same tissue section, 
with (A), (C) and (D) representing medullary regions of LN, whereas (B), (D) and (F) show cortical and subcapsular 
regions.  The boxes in (B), (D) and (F) indicate the regions of magnification (X400) represented in the 
corresponding insets. co/pa, cortex/paracortex; sc, subcapsular region.  Size bar = 100 µm (A-F). 
 
LYVE-1 mRNA.  The distributions of podoplanin+ cells that expressed Prox-1 mRNA were 
similar between uninfected and infected animals (Fig. 7C and E).  In both HLN and MLN tissue
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compartments of healthy animals, LYVE-1 mRNA was expressed by podoplanin+ cells localized 
to medullary regions or in rare discrete cortical regions, whereas podoplanin+ cells localized to 
the subcapsular regions were devoid of LYVE-1 mRNA expression (Fig. 7B and D), although 
these subcapsular cells expressed Prox-1 mRNA (Fig. 7A and C).  However, in HLNs and MLNs 
from animals infected with either SIV, M. tuberculosis or both, subsets of podoplanin+ cells 
present in subcapsular regions expressed LYVE-1 mRNA (Fig. 7F).  These data demonstrate that 
there is heterogeneity in the expression of LYVE-1 by cells at the afferent and efferent interfaces 
of LNs and that the expression of this LEC marker is affected by local infections. 
We also found granulomatous structures in some LNs from animals infected with M. 
tuberculosis.  In these LNs, the granulomas disrupted the normal LN tissue architecture and often 
occupied the majority of the tissue space.  We performed ISH on these LNs for LEC markers, the 
CCR7 ligand CCL21, and M. tuberculosis 16s rRNA.  CCL21 and podoplanin mRNAs were the 
most abundantly expressed mRNAs in these LNs.  CCL21 mRNA was expressed by cells 
predominantly in non-granulomatous regions of LN likely to be compressed LN cortex, whereas 
podoplanin mRNA was expressed by cells that formed a thick cellular band around the 
granulomas (Fig. 8A and E).  We also found that mRNAs for podoplanin, VEGFR3, Prox-1 and 
LYVE-1 were expressed by subsets of cells at the outer borders of the granulomas (Fig. 8B, C, D 
and E).  M. tuberculosis 16s rRNA was used as a surrogate marker for the presence of M. 
tuberculosis organisms/antigens and was localized primarily within the centers of the 
granulomas, although some 16s rRNA, and presumably antigen, was located within the cellular 
layer containing abundant podoplanin expression.  These data indicate that M. tuberculosis 
induced granulomas in LNs harbor cells expressing lymphatic markers and disrupt LN 
architecture and lymphatic marker distribution.   
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 Figure 7. Simultaneous in situ hybridization detection of LEC marker mRNAs combined with 
immunohistochemical staining for podoplanin in normal and infected macaque LNs.  LN tissue sections from 
uninfected, SIV infected and SIV/M. tuberculosis co-infected cynomolgus macaque were hybridized in situ with 
[35S]-labeled riboprobes specific for Prox-1 and LYVE-1 mRNAs, and immunohistochemically stained for 
podoplanin as indicated.  (A) and (G), and (B) and (H), are different regions on the same tissue section from an 
uninfected animal, with (G) and (H) representing medullary regions.  The boxes in the panels indicate the regions of 
magnification (X400) represented in the corresponding insets.  Arrows highlight select double-positive cells in each 
section.  co/pa, cortex/paracortex; sc, subcapsular region.  Size bar = 100 µm (A-H). 
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Figure 8. In situ hybridization detection of LEC and M. tuberculosis marker RNAs in granulomas 
circumscribed within LNs from M. tuberculosis infected macaques.  LN tissue sections from a M. tuberculosis 
infected cynomolgus macaque were hybridized in situ with [35S]-labeled riboprobes specific for CCL21 (A), 
VEGFR3 (B), Prox-1 (C), LYVE-1 (D), podoplanin (E), and M. tuberculosis 16s rRNA (F) RNA targets.  g, 
granuloma center.  Size bar = 100 µm (A-F). 
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Induction of CCL20 expression in lymphatic endothelial cells under inflammatory conditions in 
vivo and in vitro 
LECs can express CCL21 (57,59,199) and can produce CCL20 upon stimulation with 
inflammatory cytokines in vitro (6).  Both of these chemokines are expressed in LNs (40) and 
expression in this tissue compartment might be contributed by LECs.  To address this issue we 
performed simultaneous ISH and IHC with CCL20- or CCL21-specific riboprobes and anti-
podoplanin antibody, respectively.  Cells expressing CCL20 mRNA were localized almost 
exclusively to subcapsular regions of HLNs and MLNs, and all of these cells were podoplanin+ 
(Fig. 9A).  There was a large increase in CCL20 mRNA expression by these cells in LNs of 
animals infected with either SIV, M. tuberculosis or both (Fig. 9C and E).  In contrast, in LNs 
from both healthy and infected animals, only a subset of the podoplanin+ cells present in cortical 
and some subcapsular regions of LNs expressed mRNA for CCL21 (Fig. 9B).  The majority of 
the CCL21 mRNA expressing cells in LNs did not stain for podoplanin and were localized to the 
paracortex where few podoplanin+ cells were present (Fig. 9B and D).  These findings 
demonstrate that CCL20 is uniquely expressed by LECs and at the afferent interface of LNs, 
whereas CCL21 is expressed predominantly in the paracortex and by cells other than LECs.   
To determine whether increased expression of CCL20 mRNA by LECs in infected LNs 
could be a consequence of their interaction with components of M. tuberculosis or SIV, we 
treated hTERT-HDLECs, an in vitro LEC model (179) with γ-irradiated M. tuberculosis H37Rv 
to mimic exposure to mycobacteria or with TLR3 ligand poly(I:C) to mimic exposure to viral 
RNA.  Treatment of hTERT-HDLECs with γ-irradiated M. tuberculosis H37Rv led to a dramatic 
increase in CCL20 mRNA, which was accompanied by a concomitant increase in CCL20 protein 
levels in culture supernatants (Fig. 10A and B).  An even greater increase in expression of 
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 Figure 9. Simultaneous in situ hybridization detection of chemokine mRNAs combined with 
immunohistochemical staining for podoplanin in macaque LNs.  LN tissue sections from uninfected, SIV 
infected and M. tuberculosis infected cynomolgus macaques were hybridized in situ with [35S]-labeled riboprobes 
specific for the chemokines, CCL20 and CCL21, and immunohistochemically stained for podoplanin as indicated. 
(A-B), (C-D) and (E-F) are serial tissue sections.  The boxes in panels (A) and (B) indicate the regions of 
magnification (X400) represented in the corresponding insets.  co/pa, cortex/paracortex; sc, subcapsular region; g, 
granuloma center.  Size bar = 100 µm (A-F). 
 
CCL20  mRNA and protein was observed when hTERT-HDLECs were treated with poly(I:C) 
(Fig. 10C and D).  Interestingly, these model LECs did not express CCL21 mRNA endogenously 
nor after treatment with either γ-irradiated M. tuberculosis or poly(I:C) (data not shown).  These 
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in vitro data are consistent with our findings that CCL20 was endogenously and inducibly 
expressed in LNs uniquely by LECs, and that although CCL21 is expressed by LECs in 
peripheral tissues (57), LECs are not the major producers of CCL21 in LNs. 
 
Figure 10. Increased expression of CCL20 mRNA and protein by hTERT-HDLECs treated with model 
pathogen components.  Confluent monolayers of hTERT-HDLECs were treated with γ-irradiated M. tuberculosis 
H37Rv (A-B) or poly(I:C) (C-D) and total RNAs from the cells were analyzed for the relative induction of CCL20 
mRNA over time by real-time RT-PCR (A, C).  The amount of CCL20 released into the culture supernatants by the 
same cells was measured by ELISA (B, D). 
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4.7 CONCLUSIONS 
We have presented a comprehensive analysis of the distributions and levels of expression for 
four LEC markers and two chemokines in nonhuman primate LNs that drain two mucosal sites, 
and have examined the effects of SIV and M. tuberculosis infection on their expression in vivo.  
These findings (summarized in Table 2) provide insight into the structures and phenotypes of the 
conduits leading into and out of LNs, the organization of the interfaces between the conducting 
lymphatics and LN parenchyma, and the effects of persistent pathogens of tremendous public 
health importance on this organization.   
This study represents one of the first and most comprehensive examinations of the 
expression of multiple LEC markers in LNs and the effects of pathogenic infections on these 
patterns.  One key finding from these studies is that LECs at the afferent and efferent interfaces 
of the same LN are heterogeneous in lymphatic marker and chemokine expression.  During 
health the lymphatic marker LYVE-1 was expressed almost exclusively by LECs localized to LN 
medullary sinuses, similar to human LNs (212,213).  These findings underscore the 
heterogeneity of populations of LECs, not only throughout the body (7,214,215), but also within 
LNs.  
Interstitial fluid and cells transiting from the peripheral tissues reach the LN via the 
afferent lymphatic vessels (3,197).  In contrast, effector cells and fluids leave the LN via the 
efferent lymphatic vessels present in the medullary sinuses on their way to the blood.  Our 
demonstration that LYVE-1 is expressed almost exclusively in LN medullary sinuses, combined 
with previous reports (25,59,212) suggests that LYVE-1 might have a role in cellular egress from 
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LNs.  These interactions are especially important in the trafficking of effector T cells from this 
immune inductive site into the blood and to the necessary immune effector site.   
 
Table 2. SUMMARY OF LEC MARKER AND CHEMOKINE LOCALIZATON IN MACAQUE LNS 
 
  LN microenvironment 
 
   Cortex/ 
Marker Infection status Subcapsular Paracortex Medulla 
 
Podoplanin, VEGFR3, Prox-1 None ++a ++ + 
 SIV ++ ++ + 
 M. tuberculosis ++ ++ + 
 SIV and M. tuberculosis ++ ++ + 
 
LYVE-1 None - +++ +++ 
 SIV +/- +++ +++ 
 M. tuberculosis +/- +++ +++ 
 SIV and M. tuberculosis +/- +++ +++ 
 
CCL20 None +/- - - 
 SIV +++ - - 
 M. tuberculosis +++ - - 
 SIV and M. tuberculosis +++ - - 
 
CCL21 None + +++ + 
 SIV + +++ + 
 M. tuberculosis + +++ + 
 SIV and M. tuberculosis + +++ + 
 
 
Summarized here are the ISH findings in different LN microenvironments, with the six LEC marker- or chemokine-
specific probes in LNs from the animals infected with the indicated persistent pathogens.  aThe scoring here 
represents a summary of the levels of expression of the indicated mRNA in the different LN microenvironments 
based on the numbers of cells showing signal and the signals per cell.   
 
One challenge in understanding the implications of CCL20 and CCL21 expression in 
LNs comes from their differential expression in peripheral and lymphoid tissues.  For example, 
CCL21 is expressed by peripheral tissue afferent LECs and is important in the trafficking of 
CCR7+ DC to LNs (57), yet we have demonstrated that in LNs it is not expressed at the afferent 
interface, but rather primarily by cells in the paracortex that do not express podoplanin.  
Similarly, CCL20 is poorly expressed in skin tissue except during inflammation (216), but we 
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have shown that it is uniquely expressed at the afferent surface of LNs by podoplanin+ cells.  It is 
conceivable that the environmental context in which the LECs reside contributes to their 
chemokine expression patterns.  Based on these data, we propose that the current model of cell 
trafficking from peripheral tissues to LNs should potentially include a role for CCL20 and 
CCR6.  Cells trafficking from peripheral tissues, such as DCs, will use CCR7 to respond to LEC-
expressed CCL21 in those tissues, move into and through the lymphatic vasculature and 
encounter CCL20 at the afferent surface of the LN, perhaps responding to this signal due to 
sustained expression of CCR6.  Interestingly, CCR6 is involved in the trafficking of intestinal 
DCs to draining LNs (187).  The trafficking of cells then to the paracortical regions of LNs will 
be fine-tuned in large part by CCL21 expressed by non-LECs.  CCL20 expressed at the afferent 
face of the LN might also contribute to the localization of subsets of CCR6+ cells coming 
through high endothelial venules (HEVs) to the afferent/parenchyma interface.   
CCL20 is one of two known ligands for CCR6 and is involved in the recruitment of 
CCR6+ cells such as immature DCs (iDCs) into inflammatory sites (53,217-222).  The other 
known CCR6 ligand is the human anti-microbial peptide β-defensin 2, which is also chemotactic 
for CCR6+ cells (223).  Given that CCR6 can contribute to the migration of DCs to draining LNs 
(187), increased expression of CCL20 at the interface between the afferent lymphatics and LN 
parenchyma during a pathogenic infection could lead to enhanced recruitment of immature or 
transitional DCs into LNs.  Apart from iDCs, CCR6 is also present on effector and memory T 
cells (188), regulatory T cells (189,190), and naïve and memory B cells (191), and CCL20 
expressed by LECs in LNs likely recruits these cell types into LNs, especially during 
inflammatory conditions.  Recently it has been shown that CCR6+ cells accumulate in spleen 
during HIV-1 infection (224).  Therefore, CCL20 might contribute to recruitment of effector and 
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regulatory lymphocyte populations into lymphoid tissues that are characterized by an 
inflammatory environment due to infection, thereby ultimately affecting the regulation and 
maintenance of immune responses.  Interestingly the structural and functional properties that 
CCL20 shares with β-defensins includes potent antimicrobial properties (192,225,226).  Since 
pathogens can arrive at LNs from peripheral sites via the afferent lymphatics (69-72), the 
increased expression of CCL20 at this site during an infection might be a mechanism employed 
by the host for immediately attacking pathogens that arrive at the LN surface in afferent 
lymphatic fluid.   
We used an in vitro model of LECs and observed induction of CCL20 expression by 
LECs after treatment with either poly(I:C) or γ-irradiated M. tuberculosis H37Rv.  Poly(I:C) was 
used to model the double stranded RNA present in tissue during a local viral infection that could 
signal through TLR3 (227).  The dramatic induction of CCL20 after treatment with poly(I:C) 
indicates that LECs can bind and respond to viral components.  Similarly, treatment of LECs 
with γ-irradiated M. tuberculosis also led to dramatic increases in CCL20 expression, indicating 
that LECs can also bind and respond to mycobacterial components.  Therefore, during SIV or M. 
tuberculosis infection, both viral and bacterial components can induce CCL20 expression by 
LECs at the afferent interface in LNs.  Interestingly, even within the same LN, though, CCL20 
was not induced in cells at the efferent interface.   
We observed classical granulomas in some LNs from animals infected with M. 
tuberculosis.  These granulomas severely disrupted the LN architecture, which might in itself 
contribute to deficits in the generation and maintenance of immune responses.  Interestingly, the 
LN granulomas also contained lymphatic vessels within them.  These lymphatic vessels might 
not be contiguous with the proper lymphatic network since the granuloma itself is within the LN.  
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This organization might have adverse effects on the trafficking of cells and fluids to, from, and 
within LNs, since lymphocytes that normally exit the LN via the efferent lymphatics could be 
misguided by the lymphatic vessels present within these granulomas.   
In summary, these findings illustrate the heterogeneity of the LEC populations present at 
the afferent and efferent interfaces in LNs in health, and the alterations of the phenotypic 
characteristics of LEC populations at the afferent interface of LNs due to persistent infections.  
Since the LN has a central role in the generation and maintenance of immune responses, these 
findings can provide direction in the development of therapeutic or immunization strategies for 
combating infectious diseases or cancer metastasis in which cellular movement to or from LNs 
would need to be enhanced or inhibited, respectively.     
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5.1 PREFACE 
Following the examination of the LE network in immune inductive sites, I then focused on 
analysis of the distribution of the LE network in immune effector sites. In this section I have 
described experiments and data related to the expression of LEC and DC associated markers in 
pulmonary granulomas from M. tuberculosis infected cynomolgus macaques.  This chapter 
contains data from tissue-based analyses of chemokine, LEC and DC marker expression in 
pulmonary granulomatous tissues from M. tuberculosis-infected animals and normal lung tissues 
from healthy animals.  I have also performed in vitro studies using primary LEC and DC cultures 
to further study their interactions with M. tuberculosis.  These studies have revealed that a 
network of lymphatic vessels and DCs is present within granulomas that form during M. 
tuberculosis infection.  The in vitro experiments have revealed that LECs and DCs respond to 
mycobacterial components in a similar fashion and interestingly share a number of phenotypic 
characteristics.  I also performed a single chemokine microarray experiment using RNAs from 
primary lung LECs that were either treated with mycobacterial components or left alone 
(Appendix B).  The results from that array correlated with the changes in gene expression of 
chemokines as observed by real time RT-PCR in the same RNA samples.  Overall these studies 
provide evidence for the presence of lymphatic vessels within granulomas that form during M. 
tuberculosis infections and the potential interactions between the LE and M. tuberculosis during 
disease development. 
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5.2 ABSTRACT 
Dendritic cells (DCs) are professional antigen presenting cells that are responsible for 
surveillance of mucosal surfaces.  Antigen-loaded DCs migrate through lymphatic vessels from 
peripheral tissues to the draining lymph nodes (LNs), where they stimulate and regulate immune 
responses.  The lymphatic endothelial cells (LECs) that line the lymphatic vessels secrete the CC 
chemokine CCL21, which plays an essential role in the recruitment and migration of CCR7+ DCs 
from the peripheral tissues to the draining LNs.  Thus, interactions between DCs and LECs are 
inevitable and play a critical role in the initiation and regulation of immune responses.  DCs have 
been previously observed in granulomas, including tuberculous granulomas, whereas LECs have 
been minimally studied in these granulomas.  In this study, we used a repertoire of LEC- and 
DC-associated markers to define the composition of LEC and DC populations within tuberculous 
granulomas.  In an experimental nonhuman primate model of tuberculosis, we found abundant 
local expression of multiple DC-associated genes and focal expression of LEC markers that 
localize to likely lymphatic vessels in these granulomas.  Additionally, we found that monocyte-
derived DCs and LECs responded to γ-irradiated M. tuberculosis in a similar fashion and shared 
multiple phenotypic characteristics.  Taken altogether, these findings reveal a network of DCs 
and lymphatic vessels within pulmonary granulomas during active M. tuberculosis infection and 
suggest that LECs could potentially contribute to the inflammatory processes during infection. 
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5.3 INTRODUCTION 
Tuberculosis causes approximately 2 million deaths each year and since 1993 has been classified 
as a global health emergency by the World Health Organization (WHO).  Tuberculosis is a 
preventable disease and often curable, although multiple demographic and socioeconomic factors 
render prevention and treatment difficult. One-third of the world’s population is infected, with 
10% of the infected individuals developing active disease, usually within the first two years 
(228).  The remaining 90% of the infected population contain the infection and this clinical 
latency may persist throughout the life of the individual.  Acquired immunity to M. tuberculosis 
involves multiple T cell subsets, including CD4+ and CD8+ T cells directed against 
mycobacterial antigens (229,230). These T cells are stimulated against mycobacterial antigens by 
antigen-presenting cells (APCs), including macrophages and dendritic cells (DCs). 
DCs are a heterogeneous population of APCs that are central to the integration of innate 
and adaptive immunity.  Immature DCs, which survey the environment, have high phagocytic 
activity, but are inefficient at stimulating T cells due to their expression of MHC and 
costimulatory molecules at low levels (231).  In contrast, mature DCs have increased expression 
of MHC and costimulatory molecules and are able to migrate via lymphatic vessels from 
peripheral tissues to the regional lymph nodes (LNs), where they efficiently present the captured 
antigen to naïve T and B cells.  Immature DCs express multiple chemokine receptors, but are 
recruited primarily through CCR6 by CCL20, but also respond to CCL5 and CCL3 (232).  Upon 
maturation of DCs, CCR6 expression is downregulated and the increased expression of CCR7 on 
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mature DCs sensitizes these cells to migrate to the regional LNs via CCL21 secreted by the 
lymphatic vessels (54).   
DCs have been broadly classified into two subsets, plasmacytoid and myeloid DCs based 
on their surface expression of either CD123 (233) or CD11c, respectively.  The surface marker 
DC-SIGN (DC-specific ICAM-3 grabbing nonintegrin/CD209) has been used to classify DCs as 
immature, and functions as an adhesion molecule.  A characteristic of mature DCs is the 
expression of DC-LAMP/CD208, a lysosome-associated membrane glycoprotein homologous to 
CD68 (234).  Another group of surface markers associated with DC maturation/activation is the 
B7 family, out of which the expression of only B7-DC has been reported to be restricted to DCs, 
whereas the other B7 family members are broadly distributed on multiple hematopoietic and 
nonhematopoietic tissues (235). 
Interestingly, CD11c+ DCs have been observed within the granulomatous structures in 
patients with tuberculosis with a simultaneous reduction in CD11c+ DC in the blood (157).  In 
another study, DCs pretreated with bacillus Calmette-Guerin (BCG) augmented the polarization 
of Th1 cells (236), suggesting that trafficking of DCs to the site of the granuloma further skewed 
the immune response towards a type 1 response.  
The lymphatic endothelium (LE) is part of the lymphatic system that is involved in the 
trafficking of cells like DCs to secondary lymphoid organs and transport of interstitial fluid or 
lymph in the body.  Lymphatic endothelial cells (LECs) that make up the LE are thought to 
constitutively secrete the CCR7 ligand CCL21, which recruits CCR7+ cells, primarily mature 
DCs, to lymphatic vessels in the peripheral tissues (3).  These mature DCs then subsequently 
traffic through the lymphatic network to reach the draining LNs, where they can stimulate and 
regulate antigen-specific immune responses.  LECs have also been shown to respond to 
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inflammatory molecules by increasing expression of molecules involved in cellular trafficking 
like chemokines and adhesion molecules (57,89,90,183), which suggests that local factors can 
influence the accessibility of the lymphatic vessels for cellular traffic.  An increased presence of 
lymphatic vessels was observed in the intestine during inflammatory bowel disease suggesting 
involvement of LECs in chronic inflammatory processes (161,162).  Therefore, in pulmonary 
tuberculosis, another chronic inflammatory disease, lymphatic vessels might be involved in the 
local inflammatory processes that take place in the lung compartment. 
In this study, we sought to characterize the LEC and DC populations within the 
granulomatous lesion using LEC and DC-associated markers not previously examined in tissues 
of an experimental nonhuman primate model of tuberculosis.  We examined the expression of 
inflammatory chemokines by LECs and DCs present within these granulomas and also studied 
the response of the LECs and DCs to M. tuberculosis in vitro.  These studies have revealed the 
presence of CCL21 expressing lymphatic vessels within pulmonary granulomas and an 
abundance of DC-associated molecules at these sites that include fascin (p55), an actin bundling 
protein known to be expressed by DCs, CD11c, DC-LAMP and IL-4-INDucible protein (FIND).  
Additionally, we found that both LECs and DCs responded to M. tuberculosis by increasing 
expression of inflammatory molecules and that LECs and DCs share phenotypic similarities, 
which suggest an interesting relationship between DCs and their conduit, the lymphatic vessels.  
Overall this study demonstrates the presence of a network of DCs and lymphatic vessels within 
pulmonary granulomas formed during M. tuberculosis infection and that LECs may be more 
actively involved during infection than previously envisaged. 
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5.4 MATERIALS AND METHODS 
Animals and tissue processing 
All animal studies were performed under the guidance and approval of the University of 
Pittsburgh Institutional Animal Care and Use Committee (IACUC).  Adult cynomolgus 
macaques were inoculated with a low dose (approximately 25 colony forming units) of virulent 
M. tuberculosis (Erdman strain) via bronchoscope into the lower right lobe, as described 
elsewhere (205).  Infection was allowed to proceed until macaques reached disease states that 
spanned a spectrum from no apparent disease to advanced disease.  At necropsy, tissues were 
collected and fixed in 4% paraformaldehyde/1X phosphate buffered saline (PF/PBS) for 5 hr at 
40oC, as previously described (208).  After fixation, the tissues were cryoprotected and snap-
frozen in isopentane cooled on dry ice to -65oC. 
 
Immunohistochemistry (IHC) 
Immunohistochemical staining of 14μm tissue sections was performed using cell-type specific 
monoclonal antibodies for fascin (clone 55K-2, Dako, Carpinteria, CA), CD68 (clone KP1, 
Dako) and Podoplanin (Angiobio, Del Mar, CA).  Tissue sections were pretreated in 0.01M 
sodium citrate (pH 6.0) by microwaving followed by application of the primary antibody (diluted 
in 1X PBS) to the tissues for 1 hr in a humid chamber at room temperature.  Primary antibodies 
were detected with the SuperPicTureTM detection system (Invitrogen), using 3,3’-
diaminobenzidine (DAB) as the final substrate.  
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In situ hybridization (ISH) 
Riboprobe syntheses and ISHs were performed on 14μm tissue sections as described 
(40,207,208).  Cytokine, chemokine, LEC and DC-associated mRNAs were detected by ISH 
using gene-specific riboprobes.  Autoradiographic exposure times were 7 days for CCL20, 
CCL21 targets, 8 days for DC-LAMP, DC-SIGN, B7-DC, DC-STAMP targets, 21 days for 
CCR6, CCR7, CD123, CD11c, Podoplanin, VEGFR3, Prox1, LYVE-1 and VEGF-C targets.  
 
Combined In situ hybridization and immunohistochemistry 
Simultaneous ISH and IHC were performed as described (207,208). 
 
Immunofluorescent staining 
Immunofluorescent staining of 14μm tissue sections was performed using cell-type specific 
monoclonal antibodies for fascin (clone 55K-2, Dako, Carpinteria, CA), Ki67 (clone MM1, 
Novacastro) and Podoplanin (Angiobio, Del Mar, CA).  Tissue sections were pretreated in 
0.01M sodium citrate (pH 6.0) by microwaving followed by application of the primary antibody 
(diluted in 1X PBS) to the tissues for 1 hr in a humid chamber at room temperature.  Primary 
antibodies were detected with isotype-specific antibodies conjugated to fluorescein or biotin.  
Subsequently fluorescein and biotin conjugates were detected with an Alexa Fluor 488 signal-
amplification kit for fluorescein-conjugated probes (Invitrogen), and an Alexa Fluor 746 
conjugate of streptavidin (Invitrogen), respectively.  The slides were mounted with prolong 
antifade reagent (Invitrogen) and visualized using the Olympus Fluoview 500 confocal 
microscope (Center for Biologic Imaging, University of Pittsburgh). 
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Isolation of monocyte-derived DC 
Peripheral blood mononuclear cells were isolated from human buffy coats (Central Blood Bank) 
by Ficoll density gradient centrifugation (Histopaque, Sigma-Aldrich, ST. Louis, MO).  CD14+ 
monocytes were isolated by positive selection using anti-CD14 microbeads, per the 
manufacturer’s recommendations (Miltenyi Biotech, Auburn, CA).  The purity of CD14+ cells 
after enrichment was >90% as determined by flow cytometry.  CD14+ cells were cultured in 
RPMI 1640 media supplemented with L-glutamine (2 mM, Invitrogen), nonessential amino acids 
(100 μM, Invitrogen), 1M HEPES (Invitrogen), 10% heat-inactivated fetal calf serum (Hyclone), 
penicillin/streptomycin (100 U/100 μg, Invitrogen), IL-4 (25 ng/ml, Peprotech Inc) and GM-CSF 
(50 ng/ml, Bayer); the medium was changed on days 2 and 4.  
 
Culture of LECs 
Primary human dermal (HMVEC-dLy) and lung (HMVEC-LLy) LECs (Cambrex Bio Science) 
were cultured in EGM-2MV medium (Cambrex Bio Science) according to the supplier’s 
suggestions.  hTERT-HDLECs, kindly provided by Dr. M. S. Pepper (University of Geneva), 
were also cultured in EGM-2MV media as previously described (179). 
 
Treatment of LECs and DCs with γ-irradiated M. tuberculosis 
Confluent monolayers of LECs and immature human DCs (day 6 culture of monocyte-derived 
DC) were treated with γ-irradiated M. tuberculosis H37Rv (Colorado State University, Fort 
Collins, CO; 500 µg/ml).  This concentration has been used previously for the treatment of DCs 
(237).  The cultures were incubated in 5% CO2 at 37oC.  At the indicated time points the cells 
were harvested and the supernatants were saved.  The cells were then used for phenotypic 
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analysis that included real-time RT-PCR for multiple immune-related genes, flow cytometry for 
multiple phenotypic markers, or antigen processing assays. 
 
Phenotypic analysis of LECs and DCs 
Real-time RT-PCR (comparative Ct method) was performed as described (180) using 
commercially available TaqMan assays for multiple chemokines, cytokines and adhesion 
molecules (Applied Biosystems).  Culture supernatant levels of CCL20 and CXCL10 (R & D 
Systems), and IL-6 (BD Biosciences), were measured by ELISA.  Flow cytometry analysis was 
performed to detect the expression of CD31 (clone WM59, BD Biosciences), CD34 (clone 563, 
BD Biosciences), HLA-DR/DP/DQ (clone TU39, BD Biosciences), HLA-A,B,C (clone G46-2.6, 
BD Biosciences), CD80 (clone L307.4, BD Biosciences), CD83 (clone HB15e, BD Biosciences), 
CD86 (clone FUN1, BD Biosciences), CD40 (clone MAB89, Beckman Coulter), CD123 (clone 
7G3, BD Biosciences), DC-LAMP (CD208, clone 104.G4, Beckman Coulter), VEGFR3 (clone 
54733, R&D Systems), VCAM-1 (CD106, clone 51.10C9, BD Biosciences) and ICAM-1 
(CD54, clone HA58, BD Biosciences).  DQ-Ovalbumin (DQ-Ova, Invitrogen) was used for 
assaying the antigen uptake and processing ability of the cells.  In brief, cells (105 cells) were 
pulsed with DQ-Ova (5 μg/ml in phosphate-buffered saline) in 96-well cell culture plates (total 
volume of 100 μl) either at 37°C or 4°C for 1 hr and then the breakdown of DQ-Ova was 
assessed by flow cytometry. 
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5.5 RESULTS 
To characterize the types and locations of LEC and DC populations within tuberculous 
granulomas, we examined pulmonary granulomas from cynomolgus macaques that were 
inoculated intrabronchially with a low dose of virulent M. tuberculosis (Erdman strain).  All 
animals examined in this study were successfully infected and detailed clinicopathological and 
bacteriological findings have been presented elsewhere (205).  The pulmonary granulomas had 
abundant expression of IFN-γ-inducible chemokines and proinflammatory cytokines (156) and in 
this study we sought to define the LEC and DC populations present in granulomas in a relevant 
nonhuman primate model of tuberculosis.  
 
Expression of CCR6, CCR7 and their ligands in pulmonary granulomas 
Surveillance of the pulmonary mucosal interface with the external environment is performed by 
DCs and is characterized by their rapid turnover (238).  One of the mechanisms influencing the 
movement of DCs is the set of interactions between chemokines and chemokine receptors.  
Immature DCs express abundant CCR6, which binds CCL20, whereas mature DCs express 
CCR7, which binds CCL19 and CCL21 (239).  Therefore, we sought to determine the mRNA 
expression patterns of these two chemokine receptors within pulmonary granulomatous tissues 
using ISH.  We detected CCR7 mRNA and its expression was abundant in the lung tissues, 
specifically within the granulomas (Fig. 11A).  In contrast, CCR6 mRNA expression was 
dispersed diffusely around the granuloma (Fig. 11B).   
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 Figure 11. In situ hybridization for CCR6, CCR7 and their ligand mRNAs in pulmonary granulomatous 
tissues from cynomolgus macaques infected with virulent M. tuberculosis. CCR6 mRNA (B) was spread out 
over the granuloma, whereas CCR7 mRNA (A) was more focalized to distinct regions of the granuloma.  CCL19 
mRNA (C) was abundant and expressed as a ring on the internal portion of a cellular band ringing the granuloma, 
whereas CCL21 mRNA (E) was present as intense focal, vascular collections in the granuloma.  CCL20 mRNA (D) 
was relatively rare and localized within the cellular region of the granuloma.  Original magnifications x100 (A, B), 
x200 (C-E). 
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We also sought to determine if chemokines that recruit immature or mature DCs were 
present in granulomas.  Thus, we performed ISH for CCL20, CCL19 and CCL21 mRNA in the 
granulomatous tissues of cynomolgus macaques infected with M. tuberculosis.  Interestingly, we 
found very few CCL20+ cells expressed within granulomas (Fig.11D), whereas the CCR7 
ligands (CCL19 and CCL21) were more abundant (Fig. 11C and E).  CCL19 mRNA was 
expressed as a dispersed signal in a cellular band ringing the granulomas and was concentrated 
just outside the acellular necrotic region (Fig. 11C).  In contrast, ISH signal for CCL21 mRNA 
was intense and localized to specific sites along the outer portion of the granuloma, which 
appeared to be thin-walled vessels (Fig.11E), which were likely lymphatic vessels.  The 
distribution of CCL21 mRNA is consistent with CCR7 mRNA expression as described above, 
suggesting that CCR7+ mature DCs are present in granulomas and are localized by CCL21+ 
lymphatic vessels in these granulomas.  
 
Expression of DC-associated markers in pulmonary granulomas 
To further define the DC populations present in the pulmonary granulomas, we performed IHC 
and ISH for multiple DC targets.  We performed ISH for CD11c and CD123, to identify myeloid 
and plasmacytoid DCs respectively.  Although CD11c could be expressed by alveolar 
macrophages, we found that its mRNA (Fig. 12A and B) was abundant and dispersed throughout 
the granuloma indicating that a proportion of these cells might be myeloid DCs.  CD123 mRNA 
(Fig. 12C and D) was also expressed in granulomas and the expression was dispersed throughout 
the granulomas, but at a lower intensity than CD11c (Fig. 12).  
Fascin (p55) is a 55kDa protein involved in the formation of microfilament bundles and 
is expressed by interdigitating and follicular DCs within LNs (240), and by DCs in thymus, 
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spleen and peripheral blood (241,242).  Fascin can also be expressed by fibroblasts (243) and 
neuronal cells (244).  Fascin protein (Fig. 12G and H) and mRNA (Fig. 12E and F) had relatively 
the same distribution patterns in these granulomas, with staining observed in cells throughout the 
entire lung tissue.  The fascin+ cells were distinct from pulmonary macrophages as shown by 
simultaneous IHC for fascin and CD68 (Fig. 12I and J).  Taken together, the expression pattern 
of fascin antigen and mRNA suggests that cells expressing myeloid and plasmacytoid DC 
markers are present in granulomas. 
In addition to identifying DCs expressing lineage-specific (CD11c, CD123) and pan-DC 
(fascin) markers, we sought to obtain data regarding the maturation/activation states of the DC 
populations in granulomas.  We performed ISH for DC-SIGN, DC-LAMP and B7-DC mRNAs 
on these granulomatous tissues.  Although previous studies in rodents have shown that 
pulmonary DC populations have functional characteristics of an immature DC (231), we did not 
detect any DC-SIGN mRNA within these granulomatous tissues.  This is further supported by 
our earlier observation where we found very little CCL20 mRNA within granulomas, suggesting 
that immature DCs were not recruited to granulomas.  However, we were able to detect DC-
SIGN mRNA in some submucosal areas of the lung tissues (Fig. 13A and B).  In situ 
hybridizations for mRNA encoding the lysosomal marker DC-LAMP revealed that DC-LAMP+ 
cells encircled the granulomas  (Fig. 13C) and the ISH signal patterns in the normal lung 
architecture were consistent with our previous findings in rhesus macaques (245).  The cells 
expressing DC-LAMP mRNA were abundant on the outside surfaces of the granulomas with a 
small number of DC-LAMP mRNA+ cells also observed within the cellular portion of the 
granuloma.  These findings suggested that DCs were present in and around the granulomatous 
structure.  However, two reports have shown that DC-LAMP protein co-localizes with markers 
 81 
  
Figure 12. In situ hybridization for DC-associated mRNAs in pulmonary granulomatous tissues from 
cynomolgus macaques infected with virulent M. tuberculosis. The expression of CD11c (A, B) and CD123 (C, D) 
mRNAs were examined to determine the presence of myeloid and plasmacytoid DC. Fascin-positive cells were also 
identified in the granulomatous tissues by IHC (E, F) and ISH (G, H), with the isotype control shown (inset, C). The 
expression of fascin was restricted to DC as shown by double IHC (I, J), with fascin-positive cells (DC, brown) and 
CD68-positive cells (macrophages, red). Original magnifications, x40 (D, G), x100 (A, C, I), x400 (B, D, F, H), 
x600 (J). 
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Figure 13. In situ hybridization for DC-associated mRNAs in pulmonary granulomatous tissues from 
cynomolgus macaques infected with virulent M. tuberculosis. The expression of DC-SIGN was rare in lung 
tissues (A) and was more abundant in subregions of hilar lymph nodes (B). DC-LAMP mRNA+ cells were abundant 
surrounding the granuloma and dispersed within the cellular region of the granuloma (C). Further characterization of 
these cells showed that the DC-LAMP mRNA+ cells (D, left) were colocalized with type II pneumocytes expressing 
surfactant B mRNA (D, right). DC-STAMP mRNA expression (E) was confined to the interface between the 
caseation and cellular region of the granuloma, whereas B7-DC mRNA (F) was dispersed throughout the entire 
granuloma structure, but with increased intensity near the same interface.  Original magnifications x40 (A, C, E and 
F), x100 (B), x400 (D). 
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for human type II pneumocytes (246,247).  Thus, we examined whether the DC-LAMP ISH 
signal within the lung was consistent with these previous reports by performing ISH for 
surfactant B mRNA, which is expressed by type II pneumocytes (248).  ISH on subjacent 
sections for DC-LAMP (Fig. 13D, left) and surfactant B (Fig. 13D, right) mRNAs exhibited the 
same distribution patterns, confirming the previous findings (246,247).  These data indicate that 
the DC-LAMP mRNA expression observed in these tissues is predominantly contributed by type 
II pneumocytes that line the alveolar spaces or that are trapped within granulomas that form 
around them, and suggest that there are few DC-LAMP+ mature DCs in the pulmonary 
granulomas.  Another marker that is expressed by activated DCs is the B7 family costimulatory 
molecule, B7-DC, which is considered to be DC-restricted.  Unlike DC-LAMP, B7-DC ISH 
signal (Fig. 13F) is highly dispersed throughout and did not label distinctive cells, consistent 
with the cells potentially having numerous intertwining DC processes. 
DC-STAMP, a DC-specific transmembrane protein, is a multi-membrane spanning 
molecule that was initially described as being expressed preferentially by DC (249).  Our 
analysis of related sequences in the GenBank database revealed that FIND was identical in 
nucleotide sequence to DC-STAMP.  FIND (IL-Four INDuced) was initially described as a 
putative transmembrane molecule expressed by mononuclear phagocytes deactivated by IL-4 and 
not IL-10 treatment (250).  Next, we examined the expression of DC-STAMP/FIND mRNA in 
granulomatous tissues and found that cells expressing this IL-4-inducible mRNA were 
exquisitely localized to the cellular and acellular interface of necrotic granulomas (Fig. 4E), 
whereas DC-STAMP mRNA was not observed in solid granulomas or in normal lung tissue.  
Given that DC-STAMP and FIND are the same molecule, and that FIND was known to be 
induced by IL-4 (250), we suggest that DC-STAMP could potentially serve as a surrogate 
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marker for local IL-4 production in granulomas from cynomolgus macaques since we were not 
able to detect IL-4 mRNA in these granulomas although previously IL-4 mRNA has been 
detected in subsets of human granulomas (251), 
 
Expression of LEC markers in pulmonary granulomas 
We found expression of CCL21 mRNA in focal collections within pulmonary granulomas from 
M. tuberculosis-infected cynomolgus macaques (Fig. 11E).  Since lymphatic vessels are known 
to produce CCL21 in peripheral tissues, which is instrumental in the migration of DCs from 
peripheral tissues to draining LNs (3,59), we examined the expression of the lymphatic marker 
podoplanin by the CCL21 and CCL20 mRNA expressing cells.  We performed simultaneous ISH 
for CCL20 or CCL21 mRNA and IHC for podoplanin protein in both normal lung and 
granulomatous lung tissue sections from uninfected, healthy animals and M. tuberculosis-
infected animals. We found that all the CCL21+ cells stained for podoplanin although not all 
podoplanin+ cells expressed CCL21 mRNA (Fig. 14C and D).  Podoplanin protein was expressed 
at high levels by the cells that expressed CCL21 mRNA and that had the morphology of loosely 
structured vessels that were indicative of lymphatic vessels in both normal and granulomatous 
lung tissues, whereas it was expressed at low levels by cells that did not express CCL21 mRNA 
but were abundantly present in granulomas.  We also found that there was minimal expression of 
CCL20 mRNA by podoplanin+ cells in both normal and granulomatous lung tissues (Fig. 14A 
and B).  To further confirm the identity of lymphatic vessels, we examined the expression of 
multiple LEC marker mRNAs by the podoplanin+ cells in these lung tissues.  We performed 
simultaneous ISH/IHC for detecting the mRNA for the LEC markers podoplanin, Prox1 and 
LYVE-1 along with podoplanin protein in these tissue sections.  These markers have been 
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Figure 14. Simultaneous in situ hybridization detection of chemokine and LEC marker mRNAs combined 
with immunohistochemical staining for podoplanin in normal lung and pulmonary granulomatous tissues 
from cynomolgus macaques that were either uninfected (UI) or infected with virulent M. tuberculosis.  CCL20 
mRNA was undetectable in uninfected lung sections (A), whereas in granulomatous lung it was not expressed by 
podoplanin+ vessels (B). CCL21 mRNA was expressed by podoplanin+ vessels in both uninfected and 
granulomatous lungsC, D).  LYVE-1 and Prox1 mRNAs were minimally expressed by podoplanin+ vessels in 
uninfected lung (E, G), whereas they were highly expressed by podoplanin+ vessels in granulomatous lung (F, H).  
Podoplanin mRNA was minimally expressed by podoplanin+ vessels in uninfected lung (I), whereas it was highly 
expressed by podoplanin+ vessels and other cells present within granulomas in granulomatous lung (J).  Original 
magnification x400 (A-J). 
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widely used to identify lymphatic vessels in tissues and are known to be expressed by LECs (2).  
We found that podoplanin, Prox1 and LYVE-1 mRNAs localized to the same regions in these 
granulomas as the podoplanin+ cells that expressed CCL21 mRNA indicating that lymphatic 
vessels were present in these granulomas and that there was an increased expression of these 
marker mRNAs by the lymphatic vessels in granulomatous lung tissues compared to those in 
normal lung tissues (Fig. 14E-J).  In addition we found that both podoplanin mRNA and protein 
were also abundantly expressed by cells other than LECs in the cellular region of these 
granulomas (Fig. 14J).  These data indicate that lymphatic vessels are present within pulmonary 
granulomas of M. tuberculosis-infected cynomolgus macaques and that granulomas had high 
levels of lymphatic marker expression compared to lymphatic vessels in normal lung tissues.  
Interestingly, we also found that podoplanin+ lymphatic vessels often localized adjacent to blood 
vessels in normal lung tissues (Fig. 14A, C, E, G and I). 
 Inflammation leads to production of the lymphangiogenic factors VEGF-C and VEGF-D 
that promote the growth and proliferation of lymphatic vessels (130).  Since granulomas formed 
during M. tuberculosis infection are an inflammatory environment, we examined the expression 
of VEGF-C mRNA in these granulomas.  The expression of VEGF-C mRNA was limited in 
these granulomas to a handful of cells in the cellular regions of granulomas.  The VEGF-C 
mRNA was predominantly expressed by fascin+ cells and rarely by CD68+ macrophages or 
podoplanin+ lymphatic vessels in these granulomas (Fig. 15A).  This indicates that there is 
limited expression of the lymphangiogenic factor VEGF-C in these granulomas and that fascin+ 
cells are the primary source of VEGF-C.  We also examined the proliferation states of the 
lymphatic vessels in these granulomas and found that most of the LECs did not stain for Ki67, 
which is a known proliferation marker (Fig. 15B).  These data suggest that there is limited 
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Figure 15. Simultaneous in situ hybridization detection of VEGF-C mRNAs combined with 
immunohistochemical staining for fascin/podoplanin/CD68 and double immunofluorescent staining for Ki67 
and podoplanin in pulmonary granulomatous tissues from cynomolgus macaques infected with virulent M. 
tuberculosis.  VEGF-C mRNA was expressed by fascin+ cells and not by both podoplanin+ vessels and CD68+ 
macrophages in the granuloma(A).  Confocal images showing Ki67+ cells are present in granulomas but rarely 
colocalize with podoplanin+ vessels (B).  Original magnification x400 (A), x600 (B) 
 
expression of a lymphangiogenic factor in these granulomas, which is corroborated by the lack 
of proliferating lymphatic vessels in these granulomas. 
 
Phenotypic similarities between LECs and DCs 
Lymphatic vessels recruit CCR7+ mature DCs by the production of the CCR7 ligand CCL21 and 
act as a conduit for these DCs to reach the draining LNs.  Since we observed lymphatic vessels 
that expressed CCL21 in granulomas, we examined the distribution of DCs relative to these 
lymphatic vessels in granulomas.  We performed simultaneous ISH/IHC for CCL21 mRNA and 
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fascin protein to detect lymphatic vessels and purportedly DCs, respectively, in the same 
granulomatous sections.  Unexpectedly, we found that fascin was itself expressed by the LECs 
expressing CCL21 mRNA in granulomas suggesting co-expression of fascin by both DCs and 
LECs (Fig. 16A).  To further evaluate the expression of fascin by LECs, we performed double 
immunofluorescent staining of granulomatous sections using fascin and podoplanin specific 
antibodies.  Similar to the earlier observations, we found that the podoplanin+ lymphatic vessels 
stained for fascin providing evidence for the expression of fascin by LECs (Fig. 16B).  These 
results indicate that DCs and LECs express a common marker and suggest that they might have 
phenotypic similarities. 
Since lymphatic vessels express TLR molecules (104), they can directly bind and respond 
to pathogens.  Therefore, we evaluated the response of LECs to γ-irradiated M. tuberculosis as a 
surrogate for the live organism and its components that LECs might encounter in the granulomas 
formed during M. tuberculosis infections.  For in vitro studies, we used primary dermal 
(HMVEC-dLy) and lung (HMVEC-LLy) LECs along with model LECs, hTERT-HDLECs, 
which are dermal in origin and display a longer life-span due to the ectopic expression of human 
telomerase reverse transcriptase (179).  We observed increased expression of a panel of 
inflammatory chemokine and cytokine mRNAs in the treated LECs compared to the untreated 
control cell populations (Fig. 17A).  This response of LECs paralleled DC responses to γ-
irradiated M. tuberculosis in terms of induction of the same inflammatory molecules (Fig. 17B).  
We also found an induction in the expression of podoplanin mRNA by the DCs suggesting that 
the expression of podoplanin by cell types other than LECs in granulomas could have been 
induced due to direct interaction with the pathogen and/or the inflammatory conditions present in 
granulomas.  These data provide further evidence for the phenotypic similarities between LECs 
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Figure 16. Simultaneous in situ hybridization detection of CCL21 mRNAs combined with 
immunohistochemical staining for fascin and double immunofluorescent staining for fascin and podoplanin in 
pulmonary granulomatous tissues from cynomolgus macaques infected with virulent M. tuberculosis.  CCL21 
mRNA expressing cells stained for fascin (A) and podoplanin+ vessels also stained for fascin (B).  Original 
magnification x600 (A), x400 (B). 
 
and DCs.  We also found that these DCs did not express detectable
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levels of VEGF-C mRNA even after treatment with γ-irradiated M. tuberculosis (data not shown) 
and that there was a minimal induction in their expression of VEGF-D mRNA after treatment 
suggesting that these DCs do not produce lymphangiogenic factors in response to direct 
treatment with M. tuberculosis. 
Next we examined the expression of a subset of DC-associated molecules that included 
MHC class I/II, costimulatory molecules CD40/80/83/86, DC-LAMP and CD123 by LECs and 
found that LECs did express both MHC class I and II, CD40, DC-LAMP and CD123 (Fig. 17C) 
although the levels of MHC class II were minimal these cells also expressed negligible amounts 
of the costimulatory molecules CD80, CD83 and CD86 (data not shown).  After treatment with 
γ-irradiated M. tuberculosis, there was a slight increase in the expression level of MHC class I 
and a greater increase in CD123 by the LECs, which indicates that there are minimal changes in 
the expression levels of DC-associated molecules by LECs (Fig. 17C).  Therefore, these data 
identify similarities between LECs and DCs in both the expression of phenotypic markers and in 
some of their responses to interaction with pathogens. 
The adhesion molecules, ICAM-1 and VCAM-1 are involved in the adherence of 
immune cells to lymphatic vessels and are important for the migration of these cells through the 
lymphatic vessels (89). We found that the LECs increased surface expression of both ICAM-1 
and VCAM-1 in response to the γ-irradiated M. tuberculosis (Fig. 17D).  These data further 
support the notion that lymphatic vessels have an important role in regulation of cellular traffic 
from the periphery to LNs.  
Endothelial cells can exhibit functions that are exhibited more typically by APCs, which 
include antigen uptake, processing and presentation to T cells (252-256).  Therefore, we 
compared the LECs and DCs in their ability to take-up and process antigen using a model 
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 Figure 17. Phenotypic similarities between LECs and DCs. Confluent cultures of HMVEC-LLy (A) and 
monocyte-derived DCs (day 6, B) were either treated with γ-irradiated M. tuberculosis H37Rv (500 μg/ml) or 
medium alone (Mock). At the indicated time points total RNA was analyzed for the induction in mRNA of a panel 
of chemokine, cytokine and LEC marker genes (A and B).  The data are presented as fold-change in mRNA levels 
between the treated and mock groups for each time point and were normalized to an endogenous control mRNA.  
Also after 48 hours, the expression of the indicated immune related markers (C) and ICAM-1/VCAM-1 (D) by 
HMVEC-LLys was analyzed by flow cytometry.  Isotype controls are indicated by a dashed line (C) and the 
quadrants were set on the isotype control (D).  Similar results were obtained with HMVEC-dLys and hTERT-
HDLECs. 
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antigen DQ-Ovalbumin (DQ-Ova).  We observed that both immature DCs and LECs were able 
to process antigen and that LECs were at least as efficient at processing this model antigen 
compared to immature DCs (Fig. 18).  We also found that after treatment with γ-irradiated M. 
tuberculosis, the DCs greatly lost their ability to process antigen, whereas there was only a slight 
reduction in the LECs’ abilities to process antigen.  In contrast, HEK293 cells did not take-up 
and process this model antigen either before or after treatment with γ-irradiated M. tuberculosis 
suggesting that this phenomenon might be restricted to endothelial cells and APCs.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Antigen uptake and processing assay using DQ-Ova. Confluent cultures of HMVEC-LLy, HMVEC-
dLy, hTERT-HDLECs and HEK293 alongwith monocyte-derived dendritic cells (day 6) were either treated with γ-
irradiated M. tuberculosis H37Rv (500 μg/ml) or left alone.  After 48 hours, the cells were incubated with DQ-Ova 
either at room temperature (black lines) or 4°C (grey lines) for 1 hr and fluorescence intensity in the FITC channel 
was measured by a flow cytometer.  Representative histograms are shown for one experiment out of a total of two 
independent experiments. 
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The data presented here indicate that lymphatic vessels directly respond to M. 
tuberculosis by increasing production of inflammatory chemokines and cytokines that can recruit 
and affect immune cells, and that they also increase expression of adhesion molecules that are 
involved in the migration of these cells through these vessels.  Therefore, lymphatic vessels have 
more than a structural role to play during infection and can impact the overall outcome of the 
immune response by regulating the cellular traffic from peripheral sites of infection to LNs. 
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5.6 DISCUSSION 
In this study we have examined the local distributions of LECs and DCs in pulmonary 
granulomas resulting from intrabronchial infection of cynomolgus macaques with a low dose of 
virulent M. tuberculosis.  We have also characterized the in vitro response of LECs to M. 
tuberculosis and found that LECs share phenotypic similarities with DCs in both the expression 
of common markers and in their response to M. tuberculosis. 
Fascin+ cells were abundant in the granulomatous lesions and most of these cells are 
likely DCs.  Previous studies have shown that fascin is present in the dendritic portions and cell 
bodies of cultured Langerhans cells and the expression of fascin increased in concordance with 
the maturation of the DC (244,257).  Fascin can also be expressed by fibroblasts (243) and 
neuronal cells (244).  Although we cannot definitively state that these fascin+ cells are DCs, the 
morphological structure of the majority of these cells is consistent with their being DCs and less 
so with the fibrous-like structure of fibroblasts encircling the granuloma.  We also found that a 
minor population of fascin+ cells localized to lymphatic vessels as revealed by their co-
expression of fascin and lymphatic markers. 
Previously, we have shown that DC-LAMP mRNA expression is present in cells lining 
the alveolar walls, consisting of approximately 10-15% of the total cells (245). We have also 
shown previously that DC-LAMP mRNA was abundant in lymphoid tissues and distributed 
distinctly from DC-SIGN mRNA signals (40).  Other groups have recently shown that type II 
pneumocytes also express DC-LAMP in association with MHC class II molecules, suggesting a 
similar function in both cell types (246,247).  In the macaque tissues examined here we found 
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that DC-LAMP co-localizes in cells also expressing surfactant B, which is a type II pneumocyte 
marker in the lungs.  This suggests that the DC-LAMP mRNA we observed in macaque lung 
tissues and surrounding the granulomatous lesions are likely to be type II pneumocytes and not 
DCs.  On the other hand, the expression of the mRNA for the costimulatory molecule B7-DC in 
granulomas suggests that mature DCs are present in these structures since B7-DC expression is 
thought to be restricted to activated or mature DCs (235).  With the lack of DC-SIGN mRNA, a 
marker for immature DCs and relative abundance of B7DC mRNA in granulomas, we suggest 
that mature DCs are more abundantly present in granulomas than immature DCs. 
Mathematical modeling of M. tuberculosis infection suggests that DCs are necessary for 
the development of protective immunity against M. tuberculosis (164) and are likely involved in 
granuloma formation.  DC-recruiting chemokines have been observed in granulomas of giant cell 
arteritis and potentially are responsible for the sustained presence of DCs at the site of 
inflammation (258).  We have observed that tuberculous granulomas have cells expressing 
CCL19 and CCL21 mRNAs and they also have numerous cells expressing mature DC markers 
like B7-DC and CCR7, the receptor for CCL19/21.  These data suggest that CCR7 ligands are 
abundantly present in granulomas and are responsible for an increased presence of CCR7+ 
mature DCs in these granulomas. 
 Lymphatic vessels produce CCL21, in part to recruit CCR7 expressing cells like mature 
DCs, which has been shown to be important for regulation of immune responses (3).  We 
identified the cells expressing CCL21 mRNA in granulomas as lymphatic vessels since these 
cells also expressed the LEC markers podoplanin, VEGFR-3, LYVE-1, and Prox1.  We also 
found that there was increased localization of lymphatic vessels that expressed CCL21 mRNA in 
these granulomas compared to normal lung tissue.  These data suggest that there is a network of 
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lymphatic vessels present within granulomatous regions, which might be an outcome of the 
inflammatory conditions within these regions.   
 Increased proliferation of lymphatic vessels associated with granulomas has been 
observed in other chronic inflammatory diseases (161-163) suggesting that it is a phenomenon 
associated with chronic inflammation.  The increased density of lymphatic vessels might aid in 
the trafficking of cells like DCs from granulomas to the draining LNs, which might be important 
for regulation of immune responses and antigenic surveillance of granulomas.  It has also been 
suggested that inflammation-driven lymphatic growth might lead to development of 
dysfunctional lymphatic vessels, which could further contribute to and maintain the 
inflammation rather than help in its resolution (83).  Therefore, lymphatic vessels in granulomas 
might be impaired in their ability to drain interstitial fluid and may not allow for migration of 
recruited DCs to draining LNs.  This might explain the accumulation of fluid and retention of 
mature DCs that is observed within these granulomas.  Further evaluation of the involvement of 
the lymphatic vessels in granulomas in trafficking of cells and drainage of interstitial fluid from 
granulomas will help in resolving this issue. 
The presence of lymphatic vessels in granulomas coupled with the expression of VEGF-
C mRNA in these granulomas suggest that the inflammatory conditions within granulomas leads 
to the development of a lymphangiogenic environment supporting the growth and proliferation 
of lymphatic vessels.  Although we found that most of the lymphatic vessels in these granulomas 
did not express the proliferation marker Ki67, it could be possible that during the initial stages of 
granuloma formation there was a generation of newly formed lymphatic vessels within it and 
afterwards these vessels then lost their proliferative capacity.   
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The co-expression of fascin by LECs and DCs in granulomas indicated phenotypic 
similarities between these two cell types.  Therefore, we further investigated the similarities 
between DCs and LECs using in vitro models for both cell types.  The ability of both LECs and 
DCs to take-up and process antigen, and the increased expression of inflammatory molecules by 
both cell types in response to M. tuberculosis provided further evidence in support of their 
phenotypic similarities.  DCs have been shown to express lymphatic markers like VEGFR3 
(16,17) and differentiate into endothelial-like cells (259).  The data presented here shows that 
LECs in turn could express DC-associated markers which suggest functional plasticity between 
these two cell lineages and therefore, a more detailed analysis of their functional properties and 
interactions with each other is needed. 
Since endothelial cells have been previously shown to process and present antigen (252-
256), the data presented here suggest that similarly LECs can process antigen and as they also 
express other immune related molecules on their surface, they may also be able to present 
antigen to relevant lymphocyte populations.  Preliminary experiments indicate that the LECs are 
not as potent in activating T cells in mixed- leukocyte reactions (MLRs) as mature DCs (data not 
shown).  Therefore, assessing the capability of LECs to present antigens in multiple model 
systems needs to be explored further.   
Overall the data presented here argue for a more active role for the lymphatic 
endothelium in the inflammatory processes that occur during M. tuberculosis infections.  The 
association of lymphatic vessels with granulomas suggests the involvement of these vessels in 
regulating cellular traffic from the granuloma and may be important for the regulation of the 
immune response to M. tuberculosis.  These data also shed light on the interesting relationship 
between DCs and LECs by their expression of common phenotypic markers and may present 
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new avenues for the development of therapeutics that target DCs and require their migration 
through lymphatic vessels such as vaccines for cancer and other infectious diseases. 
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6.0  FINAL DISCUSSION 
The LE is an essential component of the mammalian vascular system.  Its vital functions include 
drainage of interstitial fluid and trafficking of immune cells to secondary lymphoid organs.  Due 
to the paucity of reliable lymphatic markers until recently, the study of the LE has been lagging 
behind that of the blood endothelium.  In the recent past, the identification of a number of 
specific molecular markers for the LE has led to better characterization of the LE in tissues and 
cultures of relatively pure LEC cultures (2).  From the perspective of the immune system, the LE 
has been studied in the development of multiple cancer types and some inflammatory diseases.  
In infectious diseases, the LE has generally been given a passing mention with its role as a 
conduit for DCs to migrate to LNs from sites of infection recognized but poorly studied.  
Mycobacterium tuberculosis and HIV-1 infections cause two major infectious diseases that have 
been declared as global pandemics and collectively cause more than 4 million deaths annually 
(152).  There has been a growing knowledge about the pathogenic mechanisms of these 
inflammatory infections, although a complete understanding of their pathogenesis is still lacking.  
Therefore, the objective of this study was to determine the response of the LE to inflammation 
and define its role during pathogenic infections using nonhuman primate models of M. 
tuberculosis and SIV infections.  We have used in vitro models of LECs to study their response 
to inflammatory mediators that included multiple TLR ligands and M. tuberculosis components.  
We have also used single-cell approaches to identify and characterize the LE networks in the 
lung and LN tissue compartments of normal and infected animals.  In addition, we examined the 
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relationship between LECs and DCs by analyzing their expression of overlapping sets of 
phenotypic markers. 
6.1 TOLL-LIKE RECEPTORS 
We found that primary LECs express most known TLR molecules except for TLR7, TLR8 and 
TLR10.  We also found that LECs are responsive to the ligands for most of these TLRs and 
respond by increasing expression of inflammatory molecules.  The expression of TLRs by LECs 
has not been studied extensively and only a limited study on the expression of TLR2 and TLR4 
by intestinal lymphatic vessels has been reported (104).  We examined primary dermal and lung 
LECs for their TLR expression and found that overall they had similar expression profiles for the 
TLR molecules.  The relatively high expression of TLR4 mRNA compared to the expression of 
TLR4 protein on the surface was a surprising result and may indicate greater stability for the 
mRNA compared to the protein for TLR4.  In contrast TLR9 protein was expressed at the 
highest levels amongst all TLRs although its mRNA levels were lower than that of most TLRs.  
These data show that mRNA levels for TLRs do not necessarily correlate with the expressed 
protein levels suggesting different stabilities for mRNA and protein and may indicate different 
mechanisms for regulation of the expression of the TLR molecules.   
 We observed that the primary LECs were responsive to five out of a panel of nine known 
ligands for TLR1-9.  The TLR3 ligand poly(I:C) induced increased expression of the maximum 
number of inflammatory genes amongst all the TLR ligands followed by the TLR4 and TLR2 
ligands LPS and Pam3CSK4 respectively.  These results indicate that LECs can recognize and 
respond to viral and bacterial components.  We also found that the primary dermal LECs were 
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more responsive than the primary lung LECs which might be reflective of their anatomic origin 
since inflammatory responses will be more tolerated in skin than in lung.  A surprising result we 
obtained was the non-responsiveness of the primary LECs to model TLR9 ligands despite their 
expression of TLR9 protein.  This suggests that these LECs express a non-functional form of 
TLR9 similar to TLR9 expression by keratinocytes and myeloid DCs (185), and HMVECs (184).  
Amongst the other TLR ligands, the TLR6 ligand FSL1 induced responses in only the primary 
dermal LECs suggesting that TLR6 expressed by the primary lung LECs might be non-
functional, whereas the TLR8 ligand ssRNA40 induced increased gene expression for only the 
CXCR3 ligands in primary LECs despite their lack of TLR8 expression indicating that maybe 
another PRR for single-stranded RNA like Retinoic acid inducible gene-I (RIG1) (172,186) may 
be involved in recognizing ssRNA40.  
 Since lymphatic vessels are conduits for DCs to migrate from the periphery to draining 
LNs, we also evaluated the effects of TLR ligands on the expression of DC recruiting 
chemokines CCL19, CCL20 and CCL21 by LECs.  To our surprise we found that none of the 
TLR ligands induced increased expression of the CCR7 ligand CCL21 by the primary LECs and 
only the cytokine OSM led to increased expression of CCL21 by the LECs as previously shown 
with mixed endothelial cell populations (183).  In contrast, we found that the CCR6 ligand 
CCL20 was induced upon stimulation with most TLR ligands suggesting that LECs could play 
an important role in the recruitment of CCR6+ immature DCs to inflamed sites.  These data are 
further supported by the increased expression of CCL20 by afferent LECs we earlier observed in 
inflamed LNs (Fig. 9C and E).  Also the close juxtaposition of blood vessels with lymphatic 
vessels as observed in normal lung tissue (Fig. 14A) suggests that CCL20 secreted by LECs 
might be able to recruit CCR6+ immature DCs from the systemic circulation, although in 
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granulomatous lung tissues we found that lymphatic vessels were not the major cell types that 
expressed CCL20 mRNA.  
 Apart from immature DCs, CCR6 is expressed by effector and memory T cells (188), a 
major proportion of regulatory T cells (189,190), and naïve and memory B cells (191).  Thus 
CCL20 expressed by LECs could contribute to the trafficking of multiple cell types through the 
lymphatic endothelial network. In addition, the increased expression of other inflammatory 
chemokines including the CXCR3 ligands, CXCL8 and CCL5 by LECs after TLR engagement 
provides further evidence for the involvement of the lymphatic vessels in the regulation of 
trafficking of multiple cell types and for the recirculation of immune effector cells during 
inflammation.  Inflammatory chemokines have been earlier shown to be produced at basal levels 
by LECs (194) and our data further expand on these findings by demonstrating the increased 
production of these chemokines by LECs on TLR engagement.   
6.2 THE LYMPHATIC ENDOTHELIUM IN GRANULOMAS 
We detected lymphatic vessels in pulmonary granulomas that formed during experimental 
infection with M. tuberculosis.  These lymphatic vessels were initially identified by their 
expression of CCL21 mRNA and further confirmed by their expression of multiple lymphatic 
markers.  These data suggest that there is an association of lymphatic vessels with granulomatous 
structures during tuberculosis.  Furthermore, we observed that lymphatic vessels within 
pulmonary granulomas had higher expression levels for lymphatic marker mRNAs, particularly 
that of Prox1, than lymphatic vessels from normal lung tissues suggesting that these lymphatic 
vessels are newly formed within granulomas.  The increased expression of lymphatic markers 
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has been correlated with the proliferation of new lymphatic vessels and is used as a marker for 
lymphangiogenesis.  Therefore, the inflammatory conditions of granulomas might create a 
lymphangiogenic environment that leads to the growth and proliferation of new lymphatic 
vessels in these structures.  It is also possible that pre-existing lymphatic vessels were entrapped 
in a developing granuloma and the inflammatory environment present in the granuloma led to 
increased expression of these lymphatic markers.   
We found that there was minimal expression of the lymphangiogenic factor VEGF-C 
mRNA in pulmonary granulomas from M. tuberculosis infected animals and that its expression 
was mostly limited to fascin+ cells rather than CD68+ macrophages.  We also observed that most 
of the lymphatic vessels within granulomas did not express the proliferation marker Ki67.  
Therefore it appears that ongoing lymphangiogenesis is not a prominent feature of the 
granulomas that we examined.  Since the animals in these study all had active tuberculosis and 
some were in advanced stages of disease progression, lymphangiogenesis might have taken place 
during the initial stages of M. tuberculosis infection and development of disease.  Also other 
lymphangiogenic factors such as VEGF-A/D, neurophilin-2 or angiopoietins might be present 
more abundantly than VEGF-C, which could contribute to the growth and proliferation of 
lymphatic vessels in granulomas.  An intriguing possibility could be that due to the lack of 
lymphangiogenesis and increased lymphatic network in these granulomas, there was a deficiency 
in the drainage of interstitial fluid and migration of cells from granulomas which led to the 
accumulation of both fluid and cells in these structures.  This might contribute to the 
pathogenesis of the infection and progression to active disease in these animals.  In a model of 
airway inflammation, blocking lymphangiogenesis led to bronchial lymphedema and 
exaggerated airflow obstruction (130) which supports the importance of lymphangiogenesis for 
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the resolution of inflammatory responses in pulmonary compartments.  Therefore, the analysis of 
the expression of lymphangiogenic factors and evaluation of lymphatic vessels for expression of 
proliferation markers in pulmonary granulomas at different stages particularly early on during M. 
tuberculosis infections will be essential for a better understanding of the role of 
lymphangiogenesis in development and maintenance of granulomas. 
In other chronic inflammatory diseases, proliferating lymphatic vessels have been 
associated with granulomatous structures.  Most notably in IBD, chronic inflammation and 
granulomatous structures were associated with increased density of lymphatic vessels (160-162).  
Therefore, our data provide further evidence for the association of lymphatic vessels with 
granulomas during chronic inflammatory diseases and suggest that these vessels might have 
important roles to play during the inflammatory process.  Inflammation-driven 
lymphangiogenesis might lead to development of dysfunctional lymphatic vessels, which could 
further contribute to and maintain the inflammation rather than help in its resolution (83).  
Therefore, examining the functional characteristics of lymphatic vessels found in granulomas 
will be crucial to determining their role in the development and maintenance of the inflammation 
during infection.   
These studies also indicate that LECs respond to multiple inflammatory mediators that 
include TLR ligands, cytokines and mycobacterial components by increasing expression of 
inflammatory chemokines and cytokines.  These data indicate that the LE can directly interact 
with and respond to these inflammatory molecules and pathogenic components.  Since 
granulomas form at sites of M. tuberculosis infection, they contain mycobacterial components 
that can directly interact with lymphatic vessels found in these granulomas.  Therefore, these 
lymphatic vessels can respond to the mycobacterial components by increasing expression of 
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inflammatory cytokines and chemokines, thus contributing to the inflammatory environment of 
these structures.  Increased production of inflammatory chemokines and cytokines will aid in the 
recruitment of immune cells to the site of infection and increased activation of cells present at 
these sites.  Further analysis of the expression of inflammatory cytokines and chemokines by the 
lymphatic vessels in granulomatous tissues will help elucidate the contribution of the LE to the 
inflammatory process during M. tuberculosis infection.   
Interestingly we found that a widely used lymphatic marker podoplanin was expressed by 
cell types other than LECs within these granulomas.  In addition, we also observed an induction 
in the expression of podoplanin mRNA by monocyte-derived DCs in vitro on treatment with γ-
irradiated M. tuberculosis.  These data indicate that podoplanin can be expressed by non-LEC 
type cells that are most likely DCs or other monocytic cells in granulomas.  DCs and other 
monocyte lineage cells have been shown to express lymphatic markers like VEGFR-3 and 
LYVE-1 under inflammatory conditions (16,17,260) which is consistent with our observations.  
Therefore, the expression of lymphatic markers by cells of the monocytic lineage suggests that 
these cells may act as a reservoir of LEC progenitor cells, which seeds the development of new 
lymphatic vessels in presence of lymphangiogenic factors at sites of infection like granulomas in 
the case of M. tuberculosis infection.   
Overall we found that lymphatic vessels were found in granulomas that contained 
abundant mature DCs with limited numbers of immature DCs and I present a model for the 
organization of a granuloma based on our in situ findings (Fig. 19).  These granulomas contained 
M. tuberculosis and M. tuberculosis-infected macrophages at their center with a surrounding ring 
of lymphocytes and macrophages.  These immune cells secrete numerous inflammatory 
cytokines and chemokines (156), which leads to the establishment of an inflammatory 
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Figure 19. A schematic representation of a granuloma.  M. tuberculosis and M. tuberculosis-infected 
macrophages are present in the center of granulomas, with a ring of lymphocytes and macrophages surrounding 
them.  Lymphatic vessels are present on the outer ring of the granuloma and mature DCs are concentrated around 
these lymphatic vessels, whereas very few immature DCs are present in these granulomas. 
 
environment within these granulomas.  The inflammatory environment also results in production 
of lymphangiogenic factors like VEGF-C primarily by DCs that causes limited growth and 
proliferation of the lymphatic vessels in these granulomas.  Since lymphatic vessels 
constitutively secrete the chemokine CCL21, an increased number of CCR7+ mature DCs are 
recruited to these granulomas due to the presence of these lymphatic vessels in granulomas.   
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6.3 HETEROGENEITY OF LYMPHATIC ENDOTHELIAL CELLS 
We have studied the lymphatic endothelial network of LNs and characterized their expression of 
multiple lymphatic markers and chemokines (summarized in Fig. 20).  We found that the LECs 
in a LN are heterogeneous in their expression of the lymphatic marker LYVE-1 and the 
chemokines CCL20 and CCL21.  Since the afferent and efferent lymphatics of a LN perform 
different functions in their localization and in the regulation of cellular traffic going into and out 
of LNs, our results further illustrate the differences amongst these two interfaces of the LNs.  
The expression of LYVE-1 mRNA almost exclusively by the LECs present at the efferent 
interfaces of LNs suggests that LYVE-1 may have a role to play in the egress of cells from LNs.  
Although studies in LYVE-1 deficient mice have shown no obvious abnormalities in terms of 
normal lymphatic function and only minimal functional alterations in lymphatic vessels were 
observed (29,30), there might be other compensatory molecules that can carry out its functions.  
Therefore, further characterization of the function of LYVE-1 in lymphatic vessels is needed.  
The expression of the chemokine CCL20 exclusively by the LECs present at the afferent 
interface of LNs suggests that it is involved in the recruitment of CCR6+ cells from the 
periphery.  Furthermore we found increased expression of CCL20 in inflamed LNs by the same 
LECs at the afferent interface of LNs, which further allude to the responsiveness of LECs to 
inflammatory signals and their production of chemokines involved in the recruitment of 
inflammatory cells.  These data demonstrate that the lymphatic network can play a more active 
role than earlier envisaged in the recruitment of immune cells and regulation of cellular traffic 
going into and out of LNs.  
The lack of expression of CCL21 mRNA by LECs in LNs compared to its high
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Figure 20. Expression of chemokines and lymphatic markers in a representative lymph node. 
 
expression seen in LECs present in the lung reflects the heterogeneity in the LEC populations 
that make up the lymphatic vascular network.  Combined with the selective expression of CCL20 
by the afferent lymphatics and LYVE-1 by the efferent lymphatics in LNs, the heterogeneous 
characteristics of LECs are further highlighted.  These data are in concordance with earlier 
reports that have also observed heterogeneity in the expression of lymphatic markers by LECs 
(7,214,215).   
The heterogeneity observed in LEC populations may be a reflection of their different 
functional and anatomical origins.  For example in LNs, the lymphatic endothelial network is 
present at both the entry and exit routes for cellular and fluid traffic.  Therefore, LECs at the 
afferent interface will be involved in the recruitment of cells and drainage of fluid from the 
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peripheral tissues via the collecting vessels of the lymphatic network and as we have observed 
inflammation can affect the expression of chemokines like CCL20 by these LECs thereby 
ultimately affecting the recruitment of the cells from the periphery into the LNs.  In contrast 
LECs at the efferent interfaces of the LNs are involved in the egress of cells from LNs.  These 
efferent LECs did not express either CCL20 or CCL21 under normal and inflammatory 
circumstances suggesting that these LECs may have a more passive role in the regulation of 
cellular egress from LNs.  Even in the lung tissue compartments we found that lymphatic vessels 
had variable expression of mRNAs for multiple lymphatic markers depending on the immune 
status of the lung.  Lungs from M. tuberculosis-infected animals had lymphatic vessels 
concentrated in granulomas and these vessels had increased expression of mRNAs for multiple 
lymphatic markers suggesting that the inflammatory environment of granulomas has specific 
effects on the expression of these markers.  We also found that lymphatic vessels in the lung did 
not express CCL20 under either normal or inflamed conditions in contrast to the increased 
expression of CCL20 observed in the afferent lymphatics of inflamed LNs.  We did observe 
increased expression of CCL20 in pulmonary granulomas in comparison to normal lung tissues 
but it was expressed by cell types other than LECs.  Overall these observations strengthen the 
argument for the prevalence of multiple LEC subtypes with different phenotypic properties 
depending on their anatomic localization and their responsiveness to environmental cues. 
6.4 PHENOTYPIC SIMILARITIES WITH DENDRITIC CELLS 
Another interesting outcome of this study has been the observation of phenotypic similarities 
between LECs and DCs.  We found that LECs express DC-associated molecules and show some 
 110 
similar functional characteristics as DCs (Fig. 16-18).  In addition, both LECs and DCs respond 
to mycobacterial components by increasing expression of the same inflammatory molecules.  
These results highlight the intriguing possibility of functional plasticity between LECs and DCs.  
A growing body of literature has provided evidence of the expression of LEC markers by DCs 
and cells of the monocytic lineage under healthy and inflammatory conditions (16,17,260).  In 
addition, monocytes have been shown to transdifferentiate into endothelial-like cells that have 
properties of LECs (129,259).  Therefore, it appears that monocytes or DCs can serve as 
endothelial progenitor cells that can seed the formation of new lymphatic vessels at sites of 
inflammation and help in increased drainage of accumulated interstitial fluid and trafficking of 
recruited cells at these sites.   
The expression of DC-associated molecules involved in immune recognition and 
activation by LECs (Fig. 17) suggests that the interactions between LECs and immune cells are 
not limited to those involved in migration but also could be involved in providing signals that 
could lead to either further activation or regulation of effector immune responses.  We have 
shown that LECs are able to take up and process a model antigen much like a DC (Fig. 18) 
which presents the interesting possibility of LECs presenting antigens to immune cells.  
Previously endothelial cells have been shown to process and present antigens to immune cells 
(252-256) and our findings provide evidence that LECs might also be able to perform similar 
functions.  Therefore, evaluation of the antigen processing and presentation capabilities of LECs 
using multiple antigenic models will help in understanding the interactions between LECs and 
immune cells.  
The increased expression of inflammatory molecules like CCL20 and IL-6 by LECs and 
DCs in response to mycobacterial components illustrates the phenotypic similarities between the 
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two cell populations.  The increased expression of the inflammatory chemokine and CCR6 
ligand CCL20 by the treated DCs suggests that immature DCs that encounter mycobacterial 
components produce chemokines that can further recruit more CCR6+ immature DCs to the site 
of infection.  Similarly LECs also can produce CCL20 which will aid in the recruitment of 
immature DCs and other CCR6+ immune cells to the site of infection.  Besides CCL20, both 
LECs and DCs increased expression of the CXCR3 ligands CXCL9 and CXCL10 in response to 
mycobacterial components.  Since these chemokines are known to recruit effector T cells, both 
LECs and DCs can contribute to the recruitment of effector cells to sites of infection.  Overall 
both LECs and DCs produce chemokines that can recruit immune cells to sites of infection, 
which provides evidence for not only phenotypic similarities between LECs and DCs but also 
their contribution to the trafficking of immune cells during infection or inflammation. 
6.5 ROLE IN INFECTION AND INFLAMMATION 
The findings presented in this dissertation provide evidence in support of a role of the LE 
in infection and inflammation.  In addition, phenotypic similarities between LECs and DCs were 
also observed.  Therefore, we propose a model in which the role of LECs parallels that of DCs 
during infection or inflammation (Fig. 21).  DCs have been widely studied and their role during 
infection and inflammation has been well established (52,261).  In contrast, LECs have been 
minimally studied in infection and inflammation.  Our findings suggest that during pathogenic 
infections, pathogens or their components can directly interact with LECs most probably through 
PRRs like TLR molecules.  In turn, LECs respond by increasing expression of inflammatory 
cytokines and chemokines that can contribute to the overall inflammatory response.  LECs might 
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also contribute to the control of infection by their production of the chemokine CCL20 and other 
such molecules, which have β-defensin–like antimicrobial properties (192,223).  In addition, 
LECs can recruit CCR6+ cells like immature DCs by their production of the CCR6 ligand 
CCL20 and lead to maturation of these immature DCs by their production of inflammatory 
cytokines.  The DCs can also affect LECs and their function by secreting lymphangiogenic 
factors that will promote lymphatic vessel growth.  Also, our findings indicate that DCs and 
other monocytic cells can express LEC markers during inflammatory conditions and that these 
cell types may infact act as progenitor cells for the seeding of new lymphatic vessels at sites of 
infection or inflammation.  Overall our findings suggest a more active role for the LE during 
infection and inflammation than previously envisaged.  
 
 
Figure 21. A schematic representation of the key interactions between LECs, DCs and infectious agents. 
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6.6 PUBLIC HEALTH SIGNIFICANCE 
The LE is an essential component of the mammalian vascular system and is at the crucial 
interface between peripheral organs and secondary lymphoid organs.  The lymphatic vascular 
network can affect the drainage of interstitial fluid from peripheral sites as well as regulate the 
cellular traffic from peripheral sites to draining LNs.  Therefore, it has an important role to play 
during inflammation and vaccination by enabling the drainage of accumulated interstitial fluid at 
inflammatory sites and also in the delivery of antigenic material from sites of infection or 
vaccination.  A thorough understanding of the regulation of these processes by the LE will aid in 
the development of better vaccine and immunotherapeutic strategies for cancer and infectious 
diseases.   
Tuberculosis is a chronic inflammatory disease that affects more than one-thirds of the 
world population.  Basic aspects of the development and pathogenesis of M. tuberculosis 
infection are known, although a comprehensive knowledge about the various players involved in 
the response to infection is still lacking.  The association of lymphatic vessels with granulomas 
that form during M. tuberculosis infection presents a new avenue to study in terms of disease 
development and pathogenesis.  Since lymphatic vessels are crucial for drainage of interstitial 
fluid and trafficking of cells, they could have considerable impact on the development, 
maintenance and resolution of granulomas.  Our results provide insight into the potential role of 
LECs during M. tuberculosis infection and will aid in the further exploration of the importance 
of the lymphatic vascular system in tuberculosis.  These could ultimately lead to development of 
novel therapeutics that targets the lymphatic endothelial network and its multifaceted functions.  
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6.7 SUMMARY 
In summary, these studies have shown that there is an association of lymphatic vessels with 
granulomatous structures that form during M. tuberculosis infection and that LECs that make up 
these vessels might have a more active role in the development, maintenance and resolution of 
inflammatory processes during infection.  In addition we have presented a study of 
heterogeneous expression of chemokines and lymphatic markers by the lymphatic endothelial 
network of LNs in health and infection.  We have also presented for the first time a 
comprehensive study of the expression of all known TLRs by primary human LECs and assessed 
the responsiveness of LECs to a panel of TLR ligands.  These studies taken together provide 
evidence for a more active role than previously appreciated for the lymphatic endothelium during 
inflammation and infection (Fig. 20).  In conclusion, this body of work provides insight into the 
functioning of the lymphatic endothelium during health and disease, and presents exciting new 
opportunities to further explore the lymphatic vascular system. 
 
 
 115 
7.0  FUTURE DIRECTIONS 
This dissertation has expanded on the understanding of the lymphatic endothelium and its 
response to inflammation and infection in in vivo and in vitro systems.  Through the course of 
these studies many pertinent questions have arisen that could not be addressed due to constraints 
of time.  The following section lists some of the key areas that could be studied further, which 
would address some of the questions that have remained unanswered. 
7.1 QUANTITATIVE AND QUALITATIVE ANALYSIS OF LYMPHATIC VESSELS 
PRESENT IN PULMONARY GRANULOMAS 
I have investigated the presence of lymphatic vessels in granulomas arising during M. 
tuberculosis infection in a cohort of animals that were in the active stages of disease progression.  
Therefore, further study needs to be performed to evaluate the lymphatic vessels in newly 
formed or early granulomatous structures in animals in the early and latent stages of infection.  
Also a quantitative estimation of lymphatic vessel density in granulomas as has been used in 
many cancer models will aid in the defining the requirement of increased lymphatic endothelial 
network for resolution or progression of infection.  Since it has been observed that chronic 
inflammation could lead to development of dysfunctional lymphatic vessels, assessing the 
normal functioning of the lymphatic vessels found in granulomas will be important.   
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7.2 
7.3 
EXPRESSION OF CHEMOKINES, CYTOKINES AND OTHER 
INFLAMMATORY MOLECULES BY LECS IN VIVO 
The studies presented here have shown that LECs can express inflammatory mediators on 
stimulation with M. tuberculosis components and cytokines.  All these studies have primarily 
been done using in vitro models with limited analysis of expression of inflammatory chemokines 
by LECs in tissues.  Therefore, the examination of the expression of inflammatory modulators by 
lymphatic vessels present in tissues obtained from animals or individuals having infection or 
other forms of inflammatory diseases would be valuable in validating the results obtained using 
in vitro models for LECs.   
EXPRESSION OF INNATE IMMUNE MOLECULES BY LECS IN VIVO AND IN 
VITRO 
I have evaluated the expression of TLR molecules by LECs in vitro.  Since TLRs represent one 
subset of a growing number of PRRs that have been identified and shown to be important 
mediators of immune responses, further study of the expression of other functional PRRs by 
LECs would help in understanding the importance of the LECs in sensing pathogens and 
modulating immune responses against them.  The expression of TLRs by lymphatic vessels and 
assessment of their responsiveness to TLR ligands in an in vivo setting will help further expand 
on the findings in my studies.  These would also aid in the development of better vaccine 
adjuvants that target TLRs and other PRRs.  
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7.4 EVALUATION OF INTERACTIONS BETWEEN LECS AND IMMUNE CELLS 
I have shown here that LECs can recruit multiple cells types and also exhibit phenotypic 
characteristics of DCs.  Further exploration of the phenotypic similarities between LECs and 
DCs in terms of antigen processing and presentation will help expand the understanding of this 
interesting phenomenon.  LECs have been shown to form tubules in 3-D matrices of collagen.  
Therefore, study of LEC tubules and immune cells in these matrices will help recreate the 
potential interactions that take place between them in vivo and may provide insight into 
functioning of the lymphatic endothelium in regulating cellular traffic. 
Overall this dissertation has led to some interesting questions and provides additional 
opportunities for the further study of the lymphatic endothelium in health and disease.  These 
studies will help in expanding our knowledge about the lymphatic endothelium and its 
underappreciated role in the host response to pathogens and their components. 
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APPENDIX A 
Table 3. ENDOTHELIUM SPECIFIC PARTIAL cDNAS. 
Gene Name 
Partial 
cDNA 
size (bp) 
% homology 
to human 
sequence 
Tissue from 
which it was 
cloned 
Note 
Pan endothelial marker 
CD31 606 95 Lung PECAM-1, Adhesion molecule 
Blood endothelial marker 
CD34 443 94 Lung Ligand for CD62L (L-selectin) 
vWF 550 97 Lung Mediates platelet adhesion to 
injured endothelium 
Lymphatic endothelial markers 
LYVE-1 530 94 Lung Hyaluronan receptor 
VEGFR-3 550 97 Lung Receptor for VEGF-C/D 
Podoplanin 560 90 Lymph node Glomerular podocyte membrane protein 
Prox-1 550 97 Lung Homeobox gene product 
Miscellaneous markers 
VEGF-C 636 98 Jejunum Lymphatic growth factor 
MR 638 97 Lymph node Mannose receptor 
Chemokine R D6 555 98 Lymph node Chemokine scavenging receptor 
Desmoplakin 629 95 Lymph node Intercellular junction protein 
Reelin 669 98 Brain Involved in neuronal development 
Plakoglobin 599 98 Lymph node Involved in cell-cell adhesion 
 
These cDNAs were cloned using gene-specific primers and total RNA from the indicated tissues obtained from 
healthy cynomolgus macaques.  Gene-specific primers were designed using conserved regions amongst human and 
other known mammalian sequences for each gene.  All sequence analysis were done using the Vector NTI software 
package (Invitrogen) 
 119 
APPENDIX B 
CHEMOKINE ARRAY EXPERIMENT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Changes in the expression of a panel of chemokine and their related mRNAs by M. tuberculosis 
treated HMVEC-LLys.  (A) Upregulated genes (fold-change>2) and (B) down regulated genes (fold-change <0.5).  
HMVEC-LLys were either left in culture (mock) or treated with γ-irradiated M. tuberculosis for 24 hrs. Total RNAs 
were then extracted and hybridized to chemokine oligo GEarrays (SuperArray) using manufacturer’s protocol.  The 
oligo GEarrays were subsequently analyzed using the GEArray Expression Analysis Suite (SuperArray) and fold-
changes were calculated using the mock as the control group. 
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